1. Introduction
Tyrosinase (TYR) (EC 1.14.18.1) is a binuclear copper-containing protein widely distributed in nature (e.g., bacteria, mammals, fungi). The structure of the enzyme can be divided into three parts: N-terminal domain, central domain, and C-terminal domain. The central domain, that represents the catalytic site, is characterized by six conserved histidine residues, coordinating two copper-oxidizing ions (Figure 1) [1].
TYR is involved in the biosynthesis of melanin. In particular, it catalyzes the oxidation of
Melanin (4) has a crucial role in skin, hair, and eye pigmentation, and in skin protection from UV radiation. For this reason, an excessive production of melanin can lead to hyperpigmentation disorders. Furthermore, the accumulation of melanin in the substantia nigra of human neurons seems related to neurodegeneration in Parkinson’s disease [3]. Thus, it is important to mitigate the excessive activity of TYR.
In recent years, several tyrosinase inhibitors (TYRIs) from natural [4] and synthetic [5,6] sources have been reported. However, the TYRIs currently employed in hyperpigmentation disorders present various side effects and the development of molecules with better pharmacological characteristics is still needed [7].
Heterocycles are cyclic structures containing one or more heteroatoms. The most recurring ones bear nitrogen, oxygen, or sulfur, but rings containing phosphorus, magnesium, selenium, and others can be found as well [8]. Heterocycles constitute privileged scaffolds as they are building blocks of many natural molecules such as DNA, RNA, proteins, vitamins, the heme group, and chlorophyll, which are essential for physiological cellular functions [9]. Due to their important biological roles, several efforts have been made towards the development of new synthetic strategies which allow access to and functionalization of heterocyclic molecules [10,11,12,13,14,15,16]. Moreover, some heterocyclic compounds were isolated from natural sources and their structures were opportunely modified [17]. It was estimated that more than 90% of new drugs present a heterocyclic moiety [9]. Heterocycles are widely applied in medicinal chemistry as they enable the formation of hydrogen bonds, and the modification of the solubility, lipophilicity, and polarity, thus facilitating the optimization of the ADMET profile of novel drug candidates [18].
For this reason, we decided to report a comprehensive review of the recent advances (last five years) of TYRIs bearing heterocycles. In particular, we organized them by taking into consideration the heterocyclic moiety and the inhibition towards the tyrosinase from the mushroom Agaricus bisporus (AbTYR) or the human tyrosinase (hTYR). This work is intended to be useful and inspiring for the scientific community in order to collect new SAR information for future developments of novel TYRIs with better pharmacological characteristics. The IC50 values or PI of all the compounds described in the manuscript are reported as Supplementary Material File.
2. Mushroom Tyrosinase Inhibitors
AbTYR [19] is usually employed for determining the inhibitory activity of TYRIs [20]. Although several differences exist between human and mushroom isoforms, the usage of the commercially available AbTYR allows a simple screening of new plausible TYRIs. Several hit compounds, detected via AbTYR, also proved to be able to inhibit hTYR-enabling anti-melanogenic effects in human cell lines, although they resulted in less potent agents [7]. Kojic acid (5), arbutin (6), ascorbic acid (7), hydroquinone (8), and rucinol (9) are well-known whitening agents and are often used as positive controls in the in vitro assays for determining anti-tyrosinase activity (Figure 2) [21].
2.1. Carbazoles
In 2019, Ghani described the anti-tyrosinase activity of seven carbazole derivatives bearing different aromatic and heteroaromatic moieties (Figure 3) [22]. These compounds (10–11, Figure 3) inhibited the diphenolase activity in a competitive manner, displaying Ki values between 1.64 and 7.48 μM, thus showing similar or better potency than kojic acid (5, Ki = 4.43 µM), which was used as a reference. The most active compound 10a carried a benzimidazole group and, according to the copper binding assay, it might inhibit TYR activity by interacting with the binuclear copper center.
2.2. Compounds Derived from Pyrrol
In 2022, Mahdavi and co-workers described a series of disubstituted 3-hydroxy-1H-pyrrol-2(5H)-one derivatives (12, Figure 4) as TYRIs [23]. Their inhibitory activity was evaluated on diphenolase activity obtaining IC50 values between 6.98 and 26.73 µM, compared to kojic acid (5, IC50 = 18.56 µM). The most active compound 12a, with an IC50 value of 6.98 µM, is a mixed-type inhibitor. SAR evaluation showed that H or small EWGs in the ortho position of R2 are favorable when R1 is a phenyl group. When a propenyl is present, however, only small EWGs in the ortho position of R2 improved the activity. In general, phenyl was the most favorable substituent in the R1 diversity site.
Zhu et al. synthesized a series of 2-cyanopyrrole derivatives (13–14, Figure 5) as TYRIs [24]. IC50 values from 0.97 to >200 µM were shown on diphenolase activity, compared to kojic acid (5, IC50 = 28.72 µM). The best result was displayed by derivative 13a with an IC50 value of 0.97 µM, which is a reversible mixed-type inhibitor (Figure 5). It also showed a good inhibitory effect on TYR in B16 melanoma cells (inhibition of 33.48%), which was almost equivalent to kojic acid (5, 39.81%).
2.3. Indole Derivatives
In 2022, Mirfazli et al. described a new series of indole derivatives (15–17, Figure 6) as TYRIs [25]. The 25 indole-carbohydrazide derivatives (15–17, Figure 6), linked to different aryl substituents, were synthesized and their biological activity was evaluated by using
Mahdavi et al. reported a series of N-phenylacetamide-oxindole-thiosemicarbazide hybrids (18, Figure 7) as TYRIs [26]. All the prepared compounds (18, Figure 7) showed TYR inhibitory activity by using
2.4. Pyrazoles
In 2018, Channar and co-workers reported the anti-tyrosinase activity of a series of aryl pyrazole derivatives (19, Figure 8) which inhibited the diphenolase activity with IC50 values in the range of 1.56 to 19.65 μM [27]. Among the tested compounds, the most effective inhibitor was derivative 19a (IC50 = 1.56 μM, shown in Figure 8) which was found to be about tenfold more active than kojic acid (5, IC50 = 16.05 μM). Kinetic analysis revealed that 19a was a non-competitive inhibitor of TYR. Docking studies suggested that 19a might occupy the enzyme active site with the 4-methoxy group oriented towards the metal ions.
Also in 2018, Chekir et al. reported a class of compounds containing three different heterocyclic moieties, which are individually known for their applications in medicinal chemistry: coumarin, pyrazole, and triazole [28]. The resulting 1,2,3-triazolo-coumarino[4,3-c]pyrazoles (20, Figure 9) were screened against different enzymes including TYR, by using
Sun and co-workers identified a series of pyrazole-resorcinol derivatives (21, Figure 10) as potent TYRIs [29]. The biological inhibition was evaluated both on monophenolase and diphenolase activities obtaining IC50 values between 0.006 and 0.79 µM, and 0.14 and 11.25 µM, respectively, compared to kojic acid (5, IC50 = 21.58 µM monophenolase; IC50 = 17.76 µM diphenolase). The most promising results were obtained for derivative 21a which possesses an IC50 value of 0.006 and 0.64 µM on monophenolase and diphenolase activities, respectively, as illustrated in Figure 10. It proved to be a promising inhibitor of TYR, melanogenesis, oxidative stress, and has great potential to be employed as an anti-Parkinsonian drug. Indeed, it can: (a) inhibit melanogenesis in a dose-dependent manner; and (b) scavenge the 2,2-diphenyl-1-picrylhydrazyl (DPPH) free radical and reduce the overproduction of LPS-induced reactive oxidative species (ROS), demonstrating its antioxidative profile. It also showed an excellent neuroprotective effect in vitro and in vivo.
2.5. Benzimidazoles
A good inhibitory activity was observed for 5-methoxy-2-mercaptobenzimidazole (22, Figure 11) by Song et al. in 2021 as a reversible and competitive inhibitor of diphenolase activity [30]. It possesses an IC50 value of 60 nM which is a promising activity in comparison to arbutin (6, IC50 = 0.48 mM) and kojic acid (5, IC50 = 22.16 µM). Molecular docking showed hydrogen bonds and hydrophobic interactions with specific amino acids residues in the A chain of TYR.
2.6. Triazoles
Triazoles are considered to be an interesting pharmacophore for developing new bioactive compounds due to their ability to form a wide spectrum of interactions with biological macromolecules, such as pi-stacking, pi-cation, hydrophobic, van der Waals, H-bonds, and coordinative bonds. Moreover, triazole represents a useful linker to join different scaffolds allowing them to obtain bifunctional chemical entities [31,32,33]. Due to its versatility, triazole has also been exploited for the design of new TYRIs. In 2018, Mahdavi and co-workers reported a new class of anti-tyrosinase agents in which the 1,2,3-triazole was combined with the benzimidazole ring [34]. As a result, eighteen derivatives (23, Figure 12) were synthesized and tested on the diphenolase activity. Six out of eighteen compounds inhibited TYR with IC50 values ranging from 9.42 to 48.00 μM. The inhibition of the most potent compound 23a (IC50 = 9.42 μM) was comparable to that of the reference kojic acid (5, IC50 = 9.28 μM) (Figure 12). Overall, the biological data pointed out that the presence of the methyl group at the C-6 position of the benzimidazole is unfavorable for activity, while the introduction of halogens in the para position of the phenyl ring linked to the triazole portion positively affected the affinity towards TYR. The analysis of the Lineweaver–Burk double reciprocal plots revealed that 23a acted as mixed-type inhibitor.
In 2019, Butt et al. described the anti-tyrosinase activity of some bi-heterocyclic N-substituted acetamides designed by combining the 2-aminothiazole with the 4-phenyl-1,2,4-triazole (24, Figure 13a) [35]. All of the compounds exhibited a good inhibitory activity against the diphenolase activity (IC50 = 0.0156–2.0181 μM) showing a stronger inhibition than kojic acid (5, IC50 = 16.832 μM). SAR analysis highlighted that the presence of small substituents in the ortho position(s) of the phenylacetamide part generally led to more effective inhibitors. This is illustrated by the most potent derivative 24a, whose IC50 value was 0.0156 μM. Moreover, the introduction of a small flexible linker between the phenyl moiety and the acetamide group also enhanced the affinity towards AbTYR. Kinetic studies showed that 24a competitively inhibited the enzyme activity. The binding mode of 24a was investigated in silico, revealing that the two phenyl rings might establish pi-stacking interactions with His259, His85, and His244. Instead, the 2-aminothiazole portion might be involved in an H-bond with Cys83 and aromatic interactions with His85. Another series of TYRIs bearing the 1,2,4-triazol-3-ylthio-N-phenyl acetamide was reported in 2020 by the same research group [36]. In vitro screening against AbTYR, by using
A variety of derivatives possessing thiosemicarbazide functionality were described as TYRIs [37,38,39] and anti-browning agents [40]. Among them Khoshneviszadeh et al. identified a new class of aryl phenoxy methyl triazole conjugated with thiosemicarbazide derivatives (26, Figure 14) as TYRIs [41]. All the compounds showed a good activity with IC50 values between 0.11 and 0.83 μM using
Akdemir and co-workers synthesized a new class of 1,2,4-triazole-thiosemicarbazide hybrid molecules (27, Figure 15) as TYRIs [42]. The activity of 32 compounds was evaluated on diphenolase activity with IC50 values from 0.0016 to >20 µM compared to kojic acid (5, IC50 = 14.09 µM). Derivatives 27a–27d showed the best activity with IC50 values of 0.00162, 0.00166, 0.00165, and 0.00197 µM, respectively (Figure 15). The main interactions of these compounds within the catalytic site of the enzyme were evaluated via molecular docking. The carbonyl group makes a hydrogen bond with the backbone of Val283 and the thiocarbazone nitrogen atoms with the side chain of Ser282. The phenyl group can be directed towards either Phe264 or Val283.
In 2022, Kloczkowski and co-workers identified a series of 1,2,4-triazole based compounds (28, Figure 16) as TYRIs [43]. Good activities were observed for almost all of the derivatives, as IC50 values were between 0.098 and 0.38 μM on diphenolase activity, compared to the positive control kojic acid (5, IC50 = 16.83 μM). Compound 28a, showing an IC50 value of 0.098 μM, is a competitive inhibitor and proved to be a good lead compound for the design of further molecules with improved pharmacological characteristics (Figure 16).
Triazole [44] and thiazole [45,46] derivatives were largely described in the literature as TYRIs. For this reason, Seo and co-workers decided to design a new class of thiazole–triazole hybrid molecules (29, Figure 17) as AbTYRIs with IC50 values between 0.0018 and 0.089 µM on diphenolase activity [47]. The best activity was observed for derivative 29a with an IC50 value of 0.0018 µM in comparison to the standard kojic acid (5, IC50 = 16.83 µM). The substitution at the benzyl ring seems to be important for obtaining a higher activity (Figure 17).
2.7. Tetrazoles
In 2018, Qamar and co-workers reported a new class of TYRIs bearing the 1,3-oxazine tetrazole scaffold (30, Figure 18) [48]. All of the synthesized compounds proved to inhibit
2.8. Furan Derivatives
In 2019, Barros et al. described the activity of keto and carboxyl furan derivatives (31–34, Figure 19) against AbTYR [49]. All the compounds were able to inhibit the enzyme with IC50 values ranging from 16.8 to 67.2 μM, employing
Jung and co-workers designed a new series of TYRIs by combining chalcone scaffolds with furan moieties [50]. The compounds designed in this fashion (35 Figure 20) inhibited the diphenolase activity with IC50 values in the range 0.28–37.36 μM, except for the 4-hydroxylphenzl, 3-metoxy-4-hydroxyphenyl, 3,5-dimetoxy-4-hydroxyphenyl, and 3-bromo-4-hydroxyphenyl substituted derivatives which showed no activity against AbTYR. The most potent compound 35a displayed a remarkably higher affinity towards the enzyme than the positive control, kojic acid (5, IC50 = 33.47 μM). According to kinetic studies, 35a is a mixed-type inhibitor and it is also able to decrease the enzyme activity in α-MSH and IBMX-stimulated B16F10 melanoma cells, reducing melanin synthesis. Moreover, a reduction of TYR expression in B16F10 cells in the presence of inhibitor 35a was detected as well.
In 2021, Figueroa-Villar et al. prepared a new class of isobenzofuran-1(3H)-ones (36, Figure 21) as TYRIs [51]. The authors employed
In 2022, Sadiq and co-workers identified a new series of (Z)-2-benzylidenebenzofuran-3(2H)-ones (37, Figure 22), also called aurones, as AbTYRIs [52]. Their activity was evaluated by using
2.9. Thiophene Derivatives
In 2018, Kim and co-workers described the anti-tyrosinase activity of eight 3-(substituted phenyl)-1-(thiophen-2-yl)prop-2-en-1-one analogs (38, Figure 23) [46]. Among the eight synthesized compounds, five derivatives were able to inhibit the oxidation of
2.10. Isoxazoles
Kim et al. reported the TYR inhibitory activity of (Z)-4-(substituted benzylidene)-3-phenylisoxazol-5(4H)-ones (39, Figure 24) with inhibition percentages in the range 72.73–24.60% [53]. The most active inhibitor 39a showed an IC50 value of 14.62 μM being more than twofold more potent than kojic acid (5, IC50 = 37.86 μM). This compound is a competitive inhibitor of TYR and, according to docking simulation, it might bind the enzyme active site by forming an H-bond with Met280 through its hydroxyl group and hydrophobic contacts with the residues Ala286, Val283, and Phe264. Furthermore, 39a was able to reduce cellular TYR activity in B16F10 melanoma cells as well as melanin synthesis.
Shaik and co-workers described a series of new isoxazole analogs (41–43, Scheme 2) of arjunolic acid (40, Scheme 2) as TYRIs [54]. After extracting the arjunolic acid (40) from the stems of X. granatum [55], the authors synthesized derivatives 41–43 via a two-step procedure. The biological assays revealed an improved inhibitory activity of derivatives 41–43 in comparison to the lead compound arjunolic acid (40, IC50 = 85.2 μM) and the reference inhibitor kojic acid (5, IC50 = 41.5 μM). The best activity was observed for 42, possessing a fluorine atom at the para position of the phenyl ring with an IC50 value of 14.3 μM.
2.11. Oxazolines
Moon and co-workers reported a series of 2-thioxooxazoline-4-one derivatives (44, Figure 25) possessing the β-phenyl-α,β-unsaturated carbonyl scaffold, which is well-known for TYR inhibition [56]. The newly prepared molecules showed an inhibitory activity between 78.05 and 4.09% in comparison to kojic acid (5, PI = 58.09%; IC50 = 23.18 µM). The two most active compounds, 44a and 44b, proved to be competitive inhibitors with IC50 values of 4.70 and 11.18 µM, respectively, and both were not cytotoxic towards B16F10 melanoma cells.
2.12. Oxadiazoles
Lee et al. described a new class of 1,3,4-oxadiazoles (45, Figure 26) as TYRIs [57]. All synthesized compounds showed an excellent inhibition of diphenolase activity with IC50 values between 0.003–0.40 µM, more pronounced than the reference, which was kojic acid (5, IC50 = 16.83 µM). Computational studies suggested that the substitution at the acetamide portion is favorable for the activity; In particular, the increment of the size of the halogen atom at the para-position increases the interactions with the enzyme improving the inhibition. The presence of the ortho-substituted methoxy phenyl group at the 5-position of the 1,3,4-oxadiazole heterocyclic ring creates a good interaction pattern with the enzyme conferring a good inhibition rate (Figure 26). In contradiction, the inhibitor 45a, which showed the best activity does not possess any substituent at the para position of the acetamide portion. Kinetic studies revealed a non-competitive mode of action, and it drastically diminished the α-MSH stimulated melanin synthesis on B16F10 cells.
A new class of 2-aminothiazole-oxadiazole bi-heterocyclic hybrids characterized by a butanamide moiety was reported by Kim and co-workers as TYRIs [58]. The synthesized compounds (46, Figure 27) showed IC50 values in the range of 0.031–1.61 μM: lower in comparison to the standard, kojic acid (5, IC50 = 16.83 µM). The two molecules 46a and 46b possessing 2-methylphenyl and 2-ethylphenyl moieties, respectively, in the phenyl ring proved to be the most active with IC50 values of 0.031 and 0.035 μM, respectively (Figure 27). Docking studies revealed good interactions with the main amino acids of the catalytic pocket.
2.13. Thiazoles
In 2018, Li et al. applied a shape-based virtual screening approach to discover new TYRIs [59]. As a result, compound 47, Figure 28, was identified as an effective TYRI on the diphenolase activity with an IC50 value of 10.3 μM. Derivative 47 acted as a competitive inhibitor and, as suggested by docking analysis, it might occupy the enzyme active site with the resorcinol moiety oriented towards the copper ions and stabilized by aromatic and hydrophobic interactions with His263, Ser282, and Val283. The thiazole moiety could form pi-stacking contacts with Phe264 while the p-phenylenediamine moiety is involved in hydrophobic interactions with Phe264 and Val248.
In the same year, Rezaei and co-workers reported the TYR inhibitory activity of a new class of azo-hydrazone tautomeric dyes bearing a thiazolididinone moiety (48, Figure 29) [60]. These derivatives (see Figure 29) were able to inhibit the diphenolase activity of AbTYR with IC50 values ranging between 37.59–140.25 μM, thus showing a lower potency if compared to the reference, kojic acid (5, IC50 = 29.44 μM). In more detail, derivative 48a proved to be the most active among the synthesized compounds, with an IC50 value of 37.59 μM. According to kinetic studies, it is a competitive inhibitor. Docking studies suggested that 48a might elicit several hydrophobic interactions and H-bonds with the residues of the catalytic pocket, which might be crucial for the binding to the active site of TYR.
Bang et al. identified the synthetic derivative (Z)-5-(3-hydroxy-4-methoxybenzylidene)-2-thioxothiazolidin-4-one (5HTM, 49, Figure 30) as AbTYR inhibitor in a cell-free based assay employing
Hydrazinyl thiazoles were exploited over the years as scaffolds for the design of new TYRIs. A successful example is represented by the study of Ghani and co-workers who synthesized a series of hydrazone-bridged thiazole-pyrrole derivatives (50, Figure 31a) whose TYR activity was evaluated by using
Piechowska et al. designed hybrid structures by combining hydrazinyl thiazole scaffolds with a tropinone ring, an alkaloid found in plants from the Solanaceae species [62,63]. The resulting compounds (51, Figure 31b) proved to inhibit the diphenolase activity of TYR with IC50 values within the range 3.22–183.34 µM. In particular, the most active compound (51a) carried the 2,4-dichloro substitution pattern on the phenyl ring, which led to an improvement of the inhibitory activity if compared to the kojic (5) and ascorbic (7) acids used as references, whose IC50 values were 72.27 μM and 386.5 μM, respectively. Concerning the inhibition mechanism, compound 51a is a non-competitive inhibitor of AbTYR.
In 2020 El-Seedi et al. designed a new series of thiourea–heterocyclic hybrids (52, Figure 32) by integrating the acyl thiourea with a 2-phenyl benzothiazole moiety [64]. The inhibition of TYR activity was evaluated for all the designed compounds by using
Bang and co-workers reported the synthesis of a new series of inhibitors (53, Figure 33) designed by combining the scaffolds of two already known classes of TYRIs, the benzylidene thiazolidinedione (54, Figure 33) [65] and the phenyl benzothiazole (55, Figure 33) [66,67]. The resulting benzylidenethiochroman-4-ones 53 were able to inhibit the monophenolase activity showing inhibition percentages between 91.5 and 8.5%. The IC50 value was computed for one of the most active compounds of this series, the (Z)-3-(hydroxyl-substituted-benzylidene)thiochroma-4-one (MHY1498, 53a) using
(Z)-5-(SubstitutedBenzylidene)-4-thioxothiazolidin-2-one derivatives (56, Figure 34) were reported by Moon and co-workers as inhibitors of AbTYR with IC50 values between 0.47 and 147.61 μM on monophenolase activity; see Figure 34 [68]. Between the synthesized compounds, seven molecules showed better activity in comparison to the reference, kojic acid (5, IC50 = 66.30). However, the best activity was obtained for 56a with an IC50 value of 0.47 μM which is a competitive inhibitor. Docking studies carried out by using a hTYR homology model revealed a possible inhibition of hTYR. Taken together, 56a proved to have better anti-melanogenic effects on B16F10 melanoma cells than kojic acid (5).
Later on, the same group described a series of (Z)-5-(substituted benzylidene)-3-phenyl-2-thioxothiazolidin-4-one compounds (57, Figure 35) as anti-melanogenic molecules [69]. Their inhibitory activity against TYR was evaluated using
The same group described also a series of 2-(substituted phenyl)-5-(trifluoromethyl)benzo[d]thiazoles derivatives (58, Figure 36) as TYRIs [70]. IC50 values between 0.2 and >300 µM were obtained on monophenolase activity, compared to kojic acid (5, IC50 = 12.6 µM). The inhibitor that showed the highest inhibitory activity is 58a with an IC50 value of 0.2 µM; 58a displayed a competitive inhibition mode, and it also inhibited cellular TYR and melanin production on B16F10 cells. In silico studies supported also a potential inhibitory activity on hTYR.
(Z)-2-Benzylidene-dihydroimidazothiazolone derivatives (59, Figure 37a), were also reported by Moon et al. as TYRIs with IC50 values between 0.88 and >100 µM using
Simpson and co-workers described two novel thiazolidin-2-imine derivatives (61–62, Figure 38) as TYRIs [73]. The two compounds 61 and 62 showed good inhibitory activities of 1.15 and 2.08 μM, respectively. These were higher in comparison to the positive control kojic acid (5, IC50 = 16.03 μM) on diphenolase activity (Figure 38). Docking studies revealed that both molecules fit well in the catalytic pocket of the enzyme and the high activity can be due to the presence of the phenyl rings that increase the hydrophobic interactions.
2.14. Hydroxypyridinones
Hydroxypyridinone is structurally related to kojic acid (5), and it also possesses anti-tyrosinase activity [74,75]. In 2018, Zhou’s research group reported a series of hydroxypyridinone derivatives (63, Figure 39) containing an oxime ether moiety, as effective TYRIs on monophenolase activity [76]. This class of inhibitors showed IC50 values in the range 1.60–22.87 μM. The most potent compound 63a (IC50 = 1.60 μM) (Figure 39) proved to be more than sevenfold more active than kojic acid (5, IC50 = 12.24 μM). The inhibitory effect of 63a on the diphenolase activity was evaluated as well. The results pointed out that 63a inhibited the oxidation of
In 2020, the same research group applied a hybridization strategy by combining the hydroxypyridinone moiety with the chalcone scaffold, which is also known to have anti-tyrosinase properties [77,78]. All of the synthesized compounds (64, Figure 40) were tested on the monophenolase activity showing inhibition percentages between 89.5 and 50.3% while the positive standard, kojic acid (5), displayed an inhibition percentage of 75.4%. The IC50 values were computed for the most potent compounds, and it was found that the most active derivative (64a) displayed IC50 values of 2.25 μM and 11.7 μM, on the monophenolase and diphenolase activities, respectively (Figure 40). As seen for the previous hydroxypyridinone derivatives, also in this case docking analysis revealed that 64a might bind TYR by coordination of the metal ions through the 4-oxy and the 5-hydroxy groups.
In 2022, Zhou’s group described a new series of stilbene–hydroxypyridinone hybrids (65, Figure 41) as TYRIs [79]. Their inhibitory activity was evaluated on monophenolase, obtaining IC50 values between 2.72 and 16.32 µM in comparison to kojic acid (5, IC50 = 12.52 µM). For the most active compound 65a, the diphenolase activity was also tested showing an IC50 value of 15.86 µM and it is a competitive-noncompetitive mixed-type inhibitor (Figure 41). Docking studies revealed that the 4-oxo function of the pyridinone ring of compound 65a coordinates the copper ion, which also showed an anti-browning effect on freshly cut apples as seen for the inhibitors previously reported by this research group.
2.15. Quinoline Derivatives
In 2019, Ullah and co-workers disclosed the anti-tyrosinase activity of a small set of dihydroquinolinone derivatives (66, Figure 42) obtained by intramolecular cyclization of the phenyl cinnamide [80]. Among the synthesized molecules, only the compound carrying the 3-hydroxy-4-methoxyphenyl substitution pattern (66a) displayed TYR inhibition on the monophenolase activity, with a percentage of 25.94 showing a potency comparable to the potency retrieved for kojic acid (5, PI = 21.39%), which was used as a reference in this study.
Acyl thiourea represents a privileged scaffold in medicinal chemistry due to its ability to coordinate metal ions [81,82]. Some acyl thiourea-containing compounds were identified as TYRIs [83]. In this context, in 2019, Mustafa et al. reported a novel class of TYRIs combining the quinoline and acyl thiourea moieties in the same molecular framework [84]. All of the resulting molecules (67, Figure 43) proved to significantly inhibit the diphenolase activity showing IC50 values in the range of 0.0070 to 1.9737 μM. Among them, the pentyl substituted derivative 67a exhibited the highest inhibition (IC50 = 70 nM) in regard to the other tested compounds and the positive standard kojic acid (5, IC50 = 16.832 μM). SAR analysis pointed out that the length of the alkyl chain greatly affects the anti-tyrosinase activity as too-short chains poorly interact with the enzyme leading to affinity loss, while too-long chains might exert the same negative effect because of the steric hindrance. Compound 67a carried a moderate alkyl chain whose length is optimal for the interaction with the enzyme. Similarly, also the presence of a phenyl ring positively influences the TYR inhibitory activity, while substituted phenyl moieties reduce the affinity due to the increment of the steric hindrance. Compound 67a acted as non-competitive TYRI and, basing on docking studies, it might bind to the enzyme by forming a H-bond with His244 through its sulfur atom, and hydrophobic contacts with Val283 and His263 by means of the aliphatic chain.
2.16. Pyrimidine-Based Derivatives
Mirmortazavi et al. designed a novel class of azo-pyrimidine containing a substituted aromatic moiety: see Figure 44 [85]. The synthesized derivatives (68, Figure 44) were tested on their diphenolase activity, whereas IC50 values in the range of 24.45–43.80 μM were observed. Two effective TYRIs, 68a and 68b, were identified which showed inhibitory potencies comparable to that of kojic acid (5, IC50 = 25.24 μM). Specifically, 68a and 68b inhibited TYR with IC50 values of 24.68 μM and 24.45 μM, respectively, displaying a non-competitive inhibition mechanism.
Debabbi and co-workers described the syntheses and anti-tyrosinase potencies of two series of compounds featuring different heterocyclic moieties in their structures, which are pyranopyrimidines (69, Figure 45) and pyranotriazolopyrimidines (70, Figure 45) [86]. The obtained compounds were tested against TYR using
Acetophenone-based 3,4-dihydropyrimidine-2(1H)-thione (71, Figure 46) was synthesized by Hökelek et al. Its inhibitory activity against TYR was evaluated on
Pozdnyakov and co-workers reported a series of 2-substituted tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidine-4(3H)-one derivatives (72, Figure 47) as TYRIs [88]. Their inhibitory activity was evaluated, showing IC50 values between 0.51 and 3.03 mM in comparison to the positive control kojic acid (5, IC50 = 0.32 mM). SAR analysis revealed that the presence of hydroxy groups increased the inhibitory activity. This was supported by molecular docking which showed that the metal–ligand interactions with the two copper ions in the catalytic site of the enzyme govern the binding mode.
2.17. Oxoquinazoline Derivatives
In 2019, Dige and co-workers reported a new class of 4-oxoquinazolin-3(4H)-yl)furan-2-carboxamides (73, Figure 48) as effective TYRIs on diphenolase activity, showing IC50 values from 0.028–1.775 μM, thus proving to be more potent than kojic acid (5, IC50 = 16.832 μM) [89]. The data obtained from the in vitro screening highlighted that the presence of EWGs on the phenyl ring is favorable for the anti-tyrosinase activity, while the introduction of EDGs led to loss of affinity. The most potent compound of this series was derivative 73a which carried two bromine atoms and one hydroxyl group on the phenyl ring. Inhibitor 73a blocked TYR activity with an IC50 value of 0.028 μM and a non-competitive inhibition mechanism.
2.18. Piperazines
De Luca and co-workers reported the anti-tyrosinase activity of some 4-fluorobenzylpiperazine derivatives. Specifically, the authors identified the 4-fluorobenzylpiperazine fragment (74, Figure 49) to be the crucial portion for the inhibitory effect on the AbTYR diphenolase activity with an IC50 value of 85.80 μM (Figure 49). The substitution of the piperazine ring with a benzoyl moiety (75, Figure 49) led to an improvement of the potency allowing to reach an IC50 value of 13.34 μM which is comparable to that of kojic acid (5, IC50 = 17.76 μM) used as a reference [90]. The decoration of the benzoyl moiety with different EWGs and EDGs increased the inhibitory activity towards TYR with the most potent compound 76 (Figure 49), which showed an IC50 value of 0.96 μM. Overall, it was observed that the substitutions in the positions 2 and 2,4 of the aroyl moiety are the most favorable for the anti-tyrosinase activity. Derivative 76 revealed to be a competitive inhibitor and was also able to reduce melanin content in α-MSH-stimulated B16F10 cells [91]. Crystallographic studies performed on Bacillus megaterium tyrosinase (BmTYR) revealed that 76 binds to the TYR active site with the fluorobenzyl moiety oriented towards the copper ions, while the rest of the molecules engage hydrophobic and H-bond interactions [90]. The replacement of the benzoyl moiety with other heteroaromatic rings (77, Figure 49) increased the inhibitory potency if compared to the unsubstituted benzoyl derivative (75), despite a reduction of the activity which was observed for this analog, with respect to compound 76 [92]. The best inhibitors of this series were the 1-naphtyl substituted 77a, the 2-naphtyl analog 77b, and the 2-thyenil derivative 77c, which displayed IC50 values of 3 μM (Figure 49).
As a continuation of the previous studies, De Luca et al. developed further TYRIs bearing the 4-fluorobenzyl piperazine portion as the pharmacophoric feature [93]. Several new compounds (78, Figure 50) were synthesized possessing substituents of different nature and their inhibition on diphenolase activity was evaluated. The obtained IC50 values (between 0.18 and 40.43 µM) were compared to the reference compound, kojic acid (5, IC50 = 17.76 μM). SAR studies suggested that the presence of a further phenyl ring (R1 substituent) is lowering the inhibitory activity, which may be due to a molecular restriction and/or steric hindrance that reduced the ability to bind the catalytic pocket. Moreover, the introduction of a more flexible linker between the phenyl moiety and the carbonyl group reduced the affinity if compared to respective aroyl analogs. In general, the di-substitution on the phenyl ring led to a better activity especially when -NO2 or -CF3 groups are in the ortho position (Figure 50). The most active compound (78a, IC50 = 0.18 µM) showed a competitive mode of action performing an anti-melanogenic effect on B16F10 cells without showing cytotoxicity.
In 2020 Abbasi et al. described the in vitro inhibitory effects of bi-heterocyclic sulfonamides containing a phenylpiperazine moiety (79, Figure 51a) against TYR employing
In the same year, De Luca and co-workers reported a small series of TYRIs bearing the phenylpiperazine and 4-hydroxylphenylpiperazine portions (80, Figure 51b), which proved to inhibit the diphenolase activity with IC50 values between 3.80 and 80.86 μM [95]. The results revealed that the hydroxy-substituted derivatives showed a better inhibition than the respective unsubstituted analogs. In particular, the most active compound 80a was about four times more potent than kojic acid (5, IC50 = 17.76 μM), displaying an IC50 value of 3.80 μM and a non-competitive inhibition mechanism. Docking simulations suggested that the higher activity observed for the hydroxy-substituted derivatives might be attributed to the ability of the hydroxyphenyl moiety to bind to the deep part of the active site with the hydroxy group oriented towards the copper ions. Furthermore, a series of (4-(4-hydroxyphenyl)piperazin-1-yl)arylmethanone derivatives (81, Figure 51c) was designed, synthesized, and their inhibitory activity against TYR was evaluated by using
Raza and co-workers designed five N-(substituted-phenyl)-4-{(4-[(E)-3-phenyl-2-propenyl]-1-piperazinyl} butanamide derivatives (82, Figure 52) based on the consideration that several effective TYRIs described in the literature carry an amide or piperazine moiety [97]. Therefore, the authors decided to combine both chemical entities by synthesizing some hybrid molecules, containing both a piperazine and a butanamide portion. All the compounds (82) showed a strong inhibition on the diphenolase activity (IC50 = 0.01–0.68 μM), superior to that of the positive standard kojic acid (5, IC50 = 16.84 μM). The most potent compound 82a (IC50 = 0.01 μM) acted as non-competitive inhibitor and showed a depigmenting effect in an in vivo zebrafish assay. Docking analysis revealed that the two aromatic rings of 82a are mainly involved in pi-stacking interactions with His85, His259, and His263.
Cinnamic acid derivatives linked to 1-aryl piperazines (83, Figure 53) were designed and synthesized by Romagnoli et al. [98]. Their inhibitory activity was evaluated by using
2.19. Quinazolines
Iraji and co-workers designed and synthesized a series of chlorophenylquinazolin-4(3H)-one derivatives (84, Figure 54) containing various aryl acetohydrazides as potential TYRIs [99]. The percentage of TYR inhibition resulted between 63.48 and 1.02%. The best activity was displayed by derivative 84a with an IC50 value of 25.48 µM, compared to kojic acid (5, IC50 = 9.30 µM).
Also quinazoline derivatives (85–86, Figure 55) were described as TYRIs by Wang et al. [100]. Some of the compounds did not show any activity whereas the IC50 values of the active molecules was between 103 and 253 µM, compared to the standard arbutin (6, IC50 = 180 µM). The most active derivative 85a was a mixed-type and reversible TYRI.
2.20. Miscellaneous
Cinnamic acid is a naturally occurring compound able to inhibit melanogenesis by inhibiting TYR activity with a low potency (IC50 = 2.10–0.21 mM) [101,102,103]. Several attempts have been carried out over the years, to improve the TYR inhibition of this natural active ingredient. One of these strategies included the synthesis of cinnamide analogs bearing a heterocyclic moiety. In this context, Ullah et al. reported the activity of several cinnamide derivatives (87, Figure 56) bearing different secondary cyclic amine, including pyrrolidine, piperidine, piperazine and morpholine [104,105]. Independently from the heterocyclic moiety, the most active compounds were those carrying a 2,4-dihydroxyphenyl portion 87a–87d, which showed inhibition percentages against the monophenolase activity ranging between 95.74 and 78.97%, proving to be more active than kojic acid (5, PI = 20.57%), which was used as positive control. All four derivatives (87a–87d) were able to inhibit melanogenesis in α-MSH stimulated B16F10 melanoma cells by reducing TYR activity. Docking suggested that the hydroxyl groups might form H-bonds mainly involving Met280 and Asn260, while the phenyl ring could elicit hydrophobic contacts with Val283, Phe264 and Ala286.
In 2019, Ghafary et al. described the synthesis and the biological evaluation of a new series of cinnamide derivatives containing a morpholine moiety (88, Figure 57) [106]. In this case, the choice of morpholine was based on the ability of this fragment to establish additional H-bonds and hydrophobic contacts with TYR binding site. Among the synthesized compounds, the mono-substituted derivatives carrying the NO2, 4-F, 3- and 4-Cl, 3-Me, the 3,4,5-triOMe and the non-substituted derivatives were able to inhibit the diphenolase activity with IC50 values between 15.2 and 75.8 μM. The most potent compound 88a displayed an affinity similar to that of kojic acid (5, IC50 = 14.4 μM), which was used as standard, and a mixed-type inhibition mechanism. According to the docking studies, the amide bond of this class of inhibitors engaged H-bonds with some residues of the active site such as Glu256, His244 and His259, while the phenyl and morpholine ring are involved in hydrophobic interactions with the surrounding residues.
2.21. Azepines
In 2019, Okajima et al. screened a library composed of 2000 compounds leading to the identification of the 5,6,7,8-tetrahydro-4H-furo[3,2-c]azepine-4-thione (T4FAT, 89, Figure 58) as new inhibitor of melanogenesis in FSK-stimulated B16F10 cells [107]. This inhibitor is characterized by a thioamide moiety which revealed to be important for the inhibition of melanin production in cell-based assays. Moreover, it displayed an efficacy about thirty times higher than kojic acid (5), used as reference in inhibiting melanogenesis in B16F10 cells. However, when tested in vitro against AbTYR by using
2.22. Chromone Derivatives
Chromone derivatives were reported in the literature as TYRIs by different groups [108,109,110]. A variety of 2-phenylchromones (90, Figure 59) was presented by Ahmed and co-workers [111]. The new derivatives were synthesized and their inhibitory activity towards TYR on diphenolase activity was evaluated. They showed IC50 values between 0.093 and 23.58 μM in comparison to the standard kojic acid (5, IC50 = 1.79 μM). Learnings from molecular docking allowed to understand that presence of bromine atoms on ring A increases the inhibitory potential of 2-phenylchromones. EDGs in ortho- and para positions of the phenyl ring B appear to be also favorable for the activity. An indole group present at the 2-position of the chromone motif since it fills large active pockets of the enzyme (Figure 59).
In 2021, Mirzaei et al. synthesized a new series of 3-hydroxyflavone derivatives (91, Figure 60) and evaluated their capabilities to inhibit TYR on diphenolase activity [110]. Some of the derivatives showed promising activity with IC50 values between 0.23 and 35.19 µM compared to kojic acid (5, IC50 = 1.79 µM). According to the biological data, the presence of substituents in the rings A and B seems favorable for a better activity. In particular, EWGs (i.e., NO2, Cl, CF3) in the para position of ring B gave the better activity meaning that these compounds fit and strongly interact with the active site of the enzyme. Highly hydrophilic (i.e., COOH) and hydrophobic (i.e., CH3 and iBu) groups on both aryl rings (A and B) are responsible for lower activities because their interaction with the enzyme are not as pronounced. Furthermore, the replacement of aryl ring B with other heterocyclics, such as thiophene (91c, IC50 = 0.347 µM), increases the activity due to the ability of the sulfur atom to coordinate with the dinuclear copper in the active site of the enzyme (Figure 60).
The same research group, documented in 2022 a new series of thioflavones and thioflavonols (92) as potential TYRIs [112]. All the synthesized compounds (92, Figure 61) showed good inhibitory activities with IC50 values between 1.12 and 5.68 µM on diphenolase activity, compared to the standard kojic acid (5, IC50 = 12.6 µM). Derivative 92a is a competitive inhibitor displaying the best inhibition with an IC50 value of 1.12 µM. The authors employed the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) test for A375 human melanoma cells for evaluating the cytotoxicity of the most promising compounds. Derivative 92a proved to be not cytotoxic. The pharmacophores decorated with the dibromo substitution on the A ring, which is fundamental for the activity, and in the B ring with EDGs, such as methyl, dimethyl amine, methoxy, or thiophene, or EWGs such as nitro or chloro, as shown in Figure 61, proved to be the most active derivatives.
2.23. Xanthone Derivatives
Xanthones are a class of oxygen containing compounds widely distributed in nature. Due to their multiple pharmacological activities, they emerged as attractive scaffold for the development of new therapeutics [113]. In this regard, the xanthone moiety was also exploited for the design of novel TYRIs. In 2019, Wu and co-workers reported a new series of 3-aryl substituted xanthone derivatives (94, Figure 62) that were screened against the diphenolase activity. All the compounds were able to inhibit the
In 2020, Resende et al. described the anti-tyrosinase activity of three xanthone derivatives bearing a catechol moiety (95–97, Figure 63) [115]. These compounds were assayed by using
Pinto et al. synthesized a series of new xanthone derivatives (98, Figure 64) which showed promising activities as TYRIs [116]. Their activity was evaluated based on diphenolase activity with IC50 values between 1.9 and 8.93 µM in comparison to kojic acid (5, IC50 = 12.81 µM). Compound 98a proved to be the best candidate with an IC50 value of 1.9 µM (Figure 64). SAR analysis suggested that bromine substitution slightly decreases the activity. Methyl substitution is favorable when a methoxy groups present in R3, R4, or R6, whereas it is not favorable when a hydroxy group is present. An aldehydic moiety is favorable when R3 and R4 are either methoxy or bromo methyl groups.
2.24. Coumarin Derivatives
Roh reported in 2021 a series of hydroxy- and geranyloxy coumarin derivatives (99–100, Figure 65) as TYRIs [117]. The activity was evaluated on diphenolase activity and arbutin (6, % inhibition = 100%) was used as positive control. The presented compounds showed a percentage of inhibition between 191 and 15% for the hydroxy derivatives, whereas between 200 and 79% for the geranyloxy substituted coumarins, at a concentration of 0.4 µM (Figure 65). In general, the geranyloxy coumarin derivatives exhibited better activity than the hydroxy coumarin derivatives, suggesting the possibility of an application of these compounds as functional cosmetic ingredients.
Fais and co-workers reported several coumarin derivatives as TYRIs [118]. In 2022, a series of phenyl and naphthyl compounds (101–102, Figure 66a) were described with IC50 values from 1.05 to >50 µM on diphenolase activity, compared to kojic acid (5, IC50 = 17.9 µM). The highest potency was observed for compound 101a with an IC50 value of 1.05 µM (Figure 66a). SAR analysis revealed that the presence of a bromine atom in meta- or para position of the phenyl ring, attached to the 3-position of the coumarin, is important for the higher activity if it is combined with at least one hydroxyl group at position seven of the coumarin moiety. In 2023, the same group described a class of hydroxylated coumarin-based thiosemicarbazones (103, Figure 66b) as TYRIs and antioxidant agents [119]. All the synthesized compounds (103) showed a higher inhibitory activity compared to the positive control, which was kojic acid (5) with IC50 values between 4.1 and 14 µM. The best activity was observed for derivatives 103a and 103b with IC50 value of 4 and 4.1 µM, respectively, which are competitive inhibitors (Figure 66b). For compounds bearing a hydroxy group attached to the coumarin ring, a mixed-type inhibition was observed. The most promising compound (103b) was found to be not cytotoxic on B16F10 cells. Molecular docking was performed, showing that the presence of a hydroxy group significantly alters the binding mode in the active site of the enzyme. Indeed, the hydroxy groups of compound 103b are oriented towards the catalytic site, whereas for compound 103a the thiosemicarbazone moiety might interact with the copper ions.
Kim and co-workers described a new class of coumarin-based thiophenyl-pyrazolylthiazole hybrids (104, Figure 67) [120]. All the synthesized compounds possess strong inhibitory activities, with IC50 between 0.043 and 4.51 µM on diphenolase activity, whereas kojic acid (5, IC50 = 18.52 µM) served as reference. The most active compound 104a has an IC50 of 0.043 µM and is a non-competitive inhibitor. Furthermore, all the compounds (104) showed a good antioxidant activity against DPPH and were found to be not cytotoxic on B16F10 melanoma cells.
2.25. Kojic Acid Derivatives
Kojic acid (5) is a fungal metabolite produced by Aspergillus and Penicillium species. It is a well-known TYRI, often used as positive control to estimate the inhibitory potential of novel anti-tyrosinase agents [121]. Kojic acid (5) is able to inhibit the monophenolase activity in a competitive manner by chelating the copper center. Moreover, it also blocks the diphenolase activity of the enzyme with a mixed-type inhibition mechanism [122]. It demonstrated also promising antioxidant capacity with photoprotective, anti-inflammatory, and pain-relieving actions [123]. However, it has some side effects since it is an irritating agent with high cytotoxicity and instability in storage [124]. In order to improve its stability, absorption, and hypopigmented effect, different structural modifications were performed [125], and several derivatives were designed to enhance its inhibitory effect on TYR. One of the adopted strategies included the linkage of kojic acid (5) with several aryl and heteroaryl moieties by a triazole linker. Within this context, Chen et al. described the synthesis and the biological evaluation of two kojic acid derivatives, KAD1 (105, Figure 68) and KAD2 (106, Figure 68) containing the phenyl allylidene hydrazine portion linked to kojic acid (5) by a 1,2,4-triazole-3-thiol ring. KAD1 and KAD2 inhibited the diphenolase activity with IC50 values of 8.33 μM and 7.50 μM, respectively, showing a higher potency than the reference kojic acid (5, IC50 = 19.50 μM) [126]. Kinetic studies revealed that both compounds act as mixed-type inhibitors [127]. Moreover, KAD2 reduced melanogenesis in B16F10 cells decreasing TYR activity and reducing the expression of different proteins involved in the melanogenic process such as TYR, TRP1, TRP2, p-PKA and p-CREB. It is noteworthy that KAD2 also suppressed melanogenesis and TYR activity in zebrafish used as vertebrate model to study the depigmenting effect of anti-melanogenic compounds [126].
Ashooriha and co-workers reported the anti-tyrosinase activity of some 1,2,3-triazole-based kojic acid derivatives in which the triazole is conjugated with different aryloxy moieties (107, Figure 68) [128]. All the resulting compounds (107) proved to be active against the diphenolase activity with IC50 values in the range of 0.06–6.80 μM, thus showing a greater inhibition than kojic acid (5, IC50 = 9.28 μM). SAR analysis unveiled that the substitution pattern of the aryloxy portion affected the inhibitory activity against AbTYR. The most active derivative was the 1-naphthyloxy analog 107a which was characterized by an IC50 value of 0.06 μM. According to the Lineweaver–Burk plot analysis, 107a inhibited TYR mostly in an uncompetitive manner. Moreover, 107a showed metal chelating ability especially towards Cu2+ ions. Docking studies suggested that 107a might bind to the enzyme active site with the 3-hydroxy-4-pyrone moiety situated close to the copper ions, while the triazole portion might engage H-bonds with His244. Instead, the naphthyl could establish hydrophobic contacts with Asn81, Cys83 and Thr324. In 2020, the same research group designed a new series of triazolo-based kojic acid analogs conjugated with different natural products endowed with anti-tyrosinase activity such as umbelliferone, sesamol, thymol, carvacrol, eugenol, isoeugenol, vanillin and isovanillin [129]. All the derivatives were tested against tyrosinase using
Karakaya et al. synthesized and tested several kojic acid derivatives (108, Figure 69) containing a substituted benzylpiperazine portion [59]. The authors also explored the 6-position of the pyranone ring by replacing the hydroxymethyl group with chloromethyl, methyl, morpholinyl methyl, piperidinyl methyl, and pyrrolidinyl methyl moieties. The tyrosinase inhibitory activity of the obtained derivatives was determined by an assay with
Khoshneviszadeh and co-workers reported a variety of thioquinazolinones conjugated to kojic acid derivatives (109, Figure 70) as potential anti-melanogenesis agents and TYRIs [130]. The inhibitory activity was evaluated using
Peng et al. reported in 2023 a series of new kojic acid-1,3,4-oxadiazole hybrids (110, Figure 71a) as TYRIs [131]. The IC50 values obtained for all the synthesized compounds (110) range from 5.32 to 19.45 µM using
The implementation of heterocyclic moieties proved to be well tolerated in potent AbTYRIs. Important for the activity seem to be the substitution patterns of several aryl rings with substituents of different nature. The best activities were observed when hydroxyl-, methoxy-, nitro-, -methyl groups, or halogens were present in the molecules. Overall, there was no functional group that proved to be the best substituent in general for AbTYR inhibition, but from each case some learnings can be drawn. These insights should be taken into consideration when novel inhibitors are designed.
3. Human Tyrosinase Inhibitors
Over the years, AbTYR has been widely employed to evaluate the depigmenting activity of potential skin whitening agents. However, many studies highlighted the differences between the AbTYR and hTYR isoforms which require diverse structural motifs for their inhibition [133]. In comparison to AbTYR, the number of reported hTYRIs is limited [134]. A study, conducted by Mann and co-workers, pointed out that some well-known TYRIs employed in topical formulations had lower affinities towards hTYR if compared to the fungal isoform [135]. To overcome these limitations, the same research group screened a library of 50,000 compounds by using the recombinant hTYR. Thiamidol (112, iso-butylamido thiazolyl resorcinol, Figure 72) proved to be most potent hTYRI identified in this screening campaign with an IC50 value of 1.1 μM. Thiamidol was tested on AbTYR as well, showing a lower affinity as displayed by the corresponding IC50 value of 108 μM. Furthermore, thiamidol was able to inhibit melanogenesis in melanocyte cultures (IC50 = 0.9 µM) revealing to be more effective than hydroquinone (IC50 = 16.3 μM) used as reference. Clinical studies disclosed the in vivo efficacy of this compound. The application twice per day in a formulation containing the 2% of the active ingredient, led to a significant whitening effect of age spots after four weeks. The putative binding mode of thiamidol into hTYR active site was probed by computational studies performed on a homology model of the protein. The outcomes revealed that the resorcinol moiety is arranged in close proximity to the metal center with the hydroxyl group in the ortho position, engaging H-bonds with Ser380. The thiazole ring is mainly involved in hydrophobic interactions while another H-bond was observed between the carbonyl group and Ser375. Later that year, the same research group, reported new insights into the SAR of thiazolyl resorcinol derivatives as hTYRIs [136]. Specifically, the authors synthesized and tested a new series of compounds bearing the aforementioned scaffold that features an amine or amide moiety. The biological data revealed that the thiazolyl resorcinol moiety is crucial for the activity. The replacement of resorcinol with other hydroxylation patterns impaired the activity, as shown for derivative 114 (Figure 72) in which the introduction of the catechol ring led to a loss of activity in comparison to the resorcinol analogue 113 (Figure 72). Similarly, the substitution of the thiazole with other aromatic or heteroaromatic rings as well as inverting the position of the thiazole had a detrimental effect on the inhibition, as exemplified by compounds 116 (Figure 72) and 117 (Figure 72), respectively, for which an affinity reduction was observed when compared to analog 115, bearing the dihydroxyphenyl moiety on the 4-position of the thiazole ring. Substitutions at the 2-amino group were tolerated better. Overall, it was observed that the amides were more active than the corresponding amines, as seen for derivatives 118 (Figure 72) and 119 (Figure 72). Moreover, small substituents positively affected the activity, while large and hydrophobic groups usually decreased the inhibition respect to more hydrophilic substituents of the same size.
In 2021, Tang et al. identified a series of proteolysis-targeting chimeras (PROTACs) as degraders of hTYR [137] (Figure 73). PROTACs are chemical compounds which provoke the degradation of specific proteins by the ubiquitin-proteasome system (UPS) [138]. They are characterized by having a portion that binds to a protein of interest, a linker and an E3 ubiquitin ligase binder. Considering the mechanism of action of a tyrosinase-targeting PROTAC, it binds to the E3 ligase and the tyrosinase at the same time. In this way the ubiquitination of the targeted TYR occurs by E3 ligase, which transfers ubiquitin units to the protein. The transfer is favored due to the close spatial arrangement. The ubiquitinylated protein is then identified by UPS and degraded. The well-established thalidomide (120) was used as E3 ligase binding portion, targeting cereblon [139]. Another popular and widely explored E3 Ligase would be the von Hippel-Lindau E3 ligase, which can be targeted by implementation of VHL ligands (121, 122) [140,141]. Kojic acid (5) and thalidomide (120, Figure 73) were chosen as main constituents of PROTACs connected by linkers of different length. However, the designed compounds (123, Figure 73) did not show promising activity and the authors decided to replace kojic acid (5) with
In 2023, Haudecoeur et al. reported a class of resorcinol-based hemiindigoid derivatives (125–126, Figure 74) as hTYRIs [143]. Their cell-based activity was evaluated on both human melanoma cell lysates and purified hTYR assays. Considering the human melanoma MNT-1 cell lysates inhibition, IC50 values between >100 and 1.57 µM were obtained, compared to the positive control rucinol (9, IC50 = 8.3 µM). For the two most active compounds 125a (IC50 = 1.57 µM) and 126a (IC50 = 1.6 µM), the MNT-1 whole cells melanogenesis inhibition, the cytotoxicity, and the kinetic parameters using a purified hTYR inhibition assay were measured and compared to kojic acid (5, IC50 = 15,000 µM; EC50 = 34,000 µM). Derivative 125a showed an IC50 value of 32 µM and a EC50 value of 108 µM on MNT-1 whole cells assay, whereas 126a presents an IC50 value of 29 µM and a EC50 value of 91 µM (Figure 74). Thus, for two derivatives, 125a and 126a, an excellent inhibition effect was observed in both human melanoma cell lysates and purified hTYR assays, showing promising results for further studies.
Considering the SAR of the reported hTYRIs, the presence of nitrogen-, sulfur-, and oxygen-containing heterocycles led to promising results for the development of more potent inhibitors. The substitution of phenyl rings with one or two hydroxyl groups seems to give the best potencies within the respective sets of inhibitors.
4. Conclusions
In conclusion, a comprehensive review of the recently described synthetic TYRIs bearing a heterocyclic structure is reported. TYR is a copper-containing enzyme which is widely present in nature. It catalyzes two consecutive oxidation steps in the biosynthesis of melanin. However, anomalies in the production of melanin can lead to serious diseases. In humans, the abnormal lack of melanin could be responsible of albinism; on the other hand, an excessive accumulation of melanin can cause disorders related to hyperpigmentation. For these reasons, TYRIs are potential skin-whitening agents and antimelanogenic substances for melanoma treatment. Due to the side effects related to the actual substances used in skin disorders, e.g., kojic acid (5) and arbutin (6), the development of new molecules with better pharmacological profile is needed. Among the inhibitors described so far, many possess heterocyclic functionalities which are fundamental for the biological activity. Thus, this review based around heterocycle-bearing TYRIs can be considered useful and inspiring for the scientific community in order to design new generations of molecules able to inhibit or even degrade tyrosinase. It can be expected that, based on learnings that can be drawn from this review, novel TYRIs will be presented to the scientific community and hopefully to patients in need of them.
Conceptualization, L.I., S.V. and C.D.; writing—review and editing, L.I., S.V. and C.D.; supervision, L.I. All authors have read and agreed to the published version of the manuscript.
Not applicable.
Not applicable.
Not applicable.
The authors thank the University of Vienna and the University of Turin for financial support. The authors acknowledge support from Project CH4.0 under MUR (Italian Ministry for the University) program “Dipartimenti di Eccellenza 2023–2027” (CUP: D13C22003520001). The authors thank Laura De Luca and Rosaria Gitto for their guidance and support throughout the years.
The authors declare no conflict of interest.
Footnotes
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
Enlarge this image.Figure 1. Three-dimensional structure of TYR with a close view on the active site of the enzyme.
Enlarge this image.Figure 2. Common TYRIs, typically used as positive controls in determining inhibitory activities.
Enlarge this image.Figure 4. 3-Hydroxy-1H-pyrrol-2(5H)-one derivatives and their inhibitory activity.
Enlarge this image.Figure 7. N-Phenylacetamide-oxindole-thiosemicarbazide hybrids (18) and their activities.
![View Image - Figure 9. Inhibitory effects of 1,2,3-triazolo-coumarino[4,3-c]pyrazole derivatives.](https://media.proquest.com/media/hms/THUM/152/ZZvnR?_a=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%2FyAgD6AgFZggMDV2ViigMcQ0lEOjIwMjUwNTEyMTUyNjQzNzYyOjkyOTUxMQ%3D%3D&_s=ahvx6exlRX2oJxxPfMIZqyvFtNY%3D "View Image - Figure 9. Inhibitory effects of 1,2,3-triazolo-coumarino[4,3-c]pyrazole derivatives.")
Enlarge this image.Figure 9. Inhibitory effects of 1,2,3-triazolo-coumarino[4,3-c]pyrazole derivatives.
Enlarge this image.Figure 13. 1,2,4-Triazol-3-ylthio-N-phenyl acetamide derivatives containing the 2-aminothiazole moiety (24) (a) and phenyl ring (25) (b) in the position five of the triazole ring.
Enlarge this image.Figure 14. Aryl phenoxy methyl triazoles conjugated with thiosemicarbazides derivatives.
Enlarge this image.Figure 19. Inhibitory activities of keto and carboxyl furan derivatives 31–34 against AbTYR.
Enlarge this image.Figure 21. Derivatives of isobenzofuran-1(3H)-one (36a) and their inhibitory profile.
Enlarge this image.Figure 22. Chemical structures of aurone derivatives 37 and their activities as AbTYRIs.
Enlarge this image.Figure 24. (Z)-4-(Substituted benzylidene)-3-phenylisoxazol-5(4H)-one derivatives.
Enlarge this image.Figure 26. The tyrosinase inhibition potential of 1,3,4-oxadiazoles derivatives 45.
Enlarge this image.Figure 27. 2-Aminothiazole-oxadiazole bi-heterocyclic hybrids 46 and their potential as AbTYR inhibitors.
Enlarge this image.Figure 28. Thiazole derivative 47 which was discovered as TYRI from virtual screening.
Enlarge this image.Figure 29. Azo-hydrazone tautomeric dyes bearing a thiazolididinone moiety derivatives.
![View Image - Figure 31. TYRIs containing hydrazinyl thiazole moieties. (a) Ghani et al. [22]; (b) Piechowska et al. [62,63].](https://media.proquest.com/media/hms/THUM/52/ZZvnR?_a=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%2FyAgD6AgFZggMDV2ViigMcQ0lEOjIwMjUwNTEyMTUyNjQzNzYyOjkyOTUxMQ%3D%3D&_s=MJmT0o9P3KycBGopoOhNNfRK%2FVg%3D "View Image - Figure 31. TYRIs containing hydrazinyl thiazole moieties. (a) Ghani et al. [22]; (b) Piechowska et al. [62,63].")
Enlarge this image.Figure 31. TYRIs containing hydrazinyl thiazole moieties. (a) Ghani et al. [22]; (b) Piechowska et al. [62,63].
Enlarge this image.Figure 32. 2-Benzothiazole-linked thioureas with inhibitory activity towards TYR.
Enlarge this image.Figure 33. Rational design of TYRIs bearing the benzylidenethiochroman-4-one scaffold.
Enlarge this image.Figure 34. (Z)-5-(Substituted benzylidene)-4-thioxothiazolidin-2-one derivatives (56) as tyrosinase inhibitors.
Enlarge this image.Figure 35. (Z)-5-(Substituted benzylidene)-3-phenyl-2-thioxothiazolidin-4-one derivatives 57, that showed promising inhibitory characteristics.
![View Image - Figure 36. Inhibitory activities towards TYR of 2-(aryl)-5-(trifluoromethyl)benzo[d]thiazoles 58.](https://media.proquest.com/media/hms/THUM/62/ZZvnR?_a=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%2FyAgD6AgFZggMDV2ViigMcQ0lEOjIwMjUwNTEyMTUyNjQzNzYyOjkyOTUxMQ%3D%3D&_s=Yg6TH2S8JA2B3kn2jAh%2BAr1A%2Biw%3D "View Image - Figure 36. Inhibitory activities towards TYR of 2-(aryl)-5-(trifluoromethyl)benzo[d]thiazoles 58.")
Enlarge this image.Figure 36. Inhibitory activities towards TYR of 2-(aryl)-5-(trifluoromethyl)benzo[d]thiazoles 58.
Enlarge this image.Figure 37. (Z)-2-Benzylidene-dihydroimidazothiazolone derivatives (59) (a). (Z)-2-(Benzylamino)-5-benzylidenethiazol-4(5H)-one derivatives (60) (b).
Enlarge this image.Figure 38. Thiazolidin-2-imine derivatives 61 and 62, with IC50 values in the very low micromolecular range.
Enlarge this image.Figure 43. Quinolinyl based acyl thiourea derivatives (67), with representative 67a reaching a single digit nanomolar IC50 value.
Enlarge this image.Figure 44. Azo-pyrimidine derivatives that were tested on their inhibitory activity on TYR.
Enlarge this image.Figure 45. TYRIs bearing the pyranopyrimidine (69) and the pyranotriazolopyrimidine (70) scaffolds.
Enlarge this image.Figure 46. Chemical structure and inhibitory activity of 3,4-dihydropyrimidine-2(1H)-thione (71).
![View Image - Figure 47. Tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidine-4(3H)-one derivatives 72, which are substituted in the 2-position.](https://media.proquest.com/media/hms/THUM/86/ZZvnR?_a=ChgyMDI1MDUxMjE1MjY0Mzc2Mjo5MDYxMzISBzEzODMzMjMaCk9ORV9TRUFSQ0giDjE4LjIxOC4yMTkuMTk1KgcyMDMyMzQxMgoyODE5NDUzMzYyOgtJbmxpbmVJbWFnZUIBMFIGT25saW5lWgNJTEliBFRIVU1qCjIwMjMvMDUvMTVyCjIwMjMvMDUvMzF6AIIBIFAtMTAwMDA4NC0yMDEzOTUtU1RBRkYtbnVsbC1udWxskgEGT25saW5lygFnTW96aWxsYS81LjAgQXBwbGVXZWJLaXQvNTM3LjM2IChLSFRNTCwgbGlrZSBHZWNrbzsgY29tcGF0aWJsZTsgQ2xhdWRlQm90LzEuMDsgK2NsYXVkZWJvdEBhbnRocm9waWMuY29tKdIBElNjaG9sYXJseSBKb3VybmFsc5oCB1ByZVBhaWSqAhtPUzpFTVMtRnVsbFRleHQtZ2V0RnVsbFRleHTKAg9BcnRpY2xlfEZlYXR1cmXiAgFO6gIFcHJpbW%2FyAgD6AgFZggMDV2ViigMcQ0lEOjIwMjUwNTEyMTUyNjQzNzYyOjkyOTUxMQ%3D%3D&_s=Nt8MJkkF9kzZ83FI%2FROrpU%2F%2FrDw%3D "View Image - Figure 47. Tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidine-4(3H)-one derivatives 72, which are substituted in the 2-position.")
Enlarge this image.Figure 47. Tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidine-4(3H)-one derivatives 72, which are substituted in the 2-position.
Enlarge this image.Figure 48. Oxoquinazoline derivatives 73 and their potential in inhibition of TYR.
Enlarge this image.Figure 50. Further 4-fluorobenzylpiperazine derivatives (78) which were identified as TYRIs.
![View Image - Figure 51. Phenylpiperazine TYRIs (79–81) from various studies. (a) Abbassi et al. [94]; (b) De Luca et al. [95]; (c) De Luca et al. [96].](https://media.proquest.com/media/hms/THUM/96/ZZvnR?_a=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%2FyAgD6AgFZggMDV2ViigMcQ0lEOjIwMjUwNTEyMTUyNjQzNzYyOjkyOTUxMQ%3D%3D&_s=TFnk80g6HRyYiuxlS9Zt49NhBHo%3D "View Image - Figure 51. Phenylpiperazine TYRIs (79–81) from various studies. (a) Abbassi et al. [94]; (b) De Luca et al. [95]; (c) De Luca et al. [96].")
Enlarge this image.Figure 51. Phenylpiperazine TYRIs (79–81) from various studies. (a) Abbassi et al. [94]; (b) De Luca et al. [95]; (c) De Luca et al. [96].
Enlarge this image.Figure 54. Chlorophenylquinazolin-4(3H)-one derivatives 84 with inhibitory potential of TYR.
Enlarge this image.Figure 55. Quinazoline derivatives 85 and 86 in three-digit micromolar range of TYR inhibition.
Enlarge this image.Figure 56. Cinnamide derivatives and their percentage of inhibition of monophenolase.
Enlarge this image.Figure 61. Thioflavones and thioflavonols derivatives and their activities on TYR inhibition.
Enlarge this image.Figure 62. 1-hydroxyl xanthone (93), and derived 3-aryl substituted xanthone derivatives and their TYR inhibitory potencies.
Enlarge this image.Figure 63. Catechol-containing-xanthone derivatives 95–97 and their IC50 values on TYR.
Enlarge this image.Figure 64. Further xanthone derivatives with promising inhibitory activity of TYR.
![View Image - Figure 66. Coumarin derivatives with either aryl groups (101 and 102, (a) Fais et al. [118]) or thiosemicarbazone (103, (b) Fais et al. [119]) groups in the 3-position.](https://media.proquest.com/media/hms/THUM/128/ZZvnR?_a=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%2FyAgD6AgFZggMDV2ViigMcQ0lEOjIwMjUwNTEyMTUyNjQzNzYyOjkyOTUxMQ%3D%3D&_s=XHh3PRi6RHaP9WR0Rq91tacILCI%3D "View Image - Figure 66. Coumarin derivatives with either aryl groups (101 and 102, (a) Fais et al. [118]) or thiosemicarbazone (103, (b) Fais et al. [119]) groups in the 3-position.")
Enlarge this image.Figure 66. Coumarin derivatives with either aryl groups (101 and 102, (a) Fais et al. [118]) or thiosemicarbazone (103, (b) Fais et al. [119]) groups in the 3-position.
Enlarge this image.Figure 67. Coumarin-based thiophenyl-pyrazolylthiazole hybrids which show good activity in TYR inhibition.
Enlarge this image.Figure 68. Triazole-based kojic acid derivatives 105–107 and their inhibitory profile on TYR.
Enlarge this image.Figure 69. Kojic acid derivatives containing a benzylpiperazine portion (108) and their TYR inhibition.
Enlarge this image.Figure 70. Thioquinazolinones conjugated to kojic acid derivatives (109) showing medium 3-digit nanomolar activity as TYRIs.
Supplementary Materials
The following supporting information can be downloaded at:
References
1. Solano, F. On the metal cofactor in the tyrosinase family. Int. J. Mol. Sci.; 2018; 19, 633. [DOI: https://dx.doi.org/10.3390/ijms19020633] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/29473882]
2. Kanteev, M.; Goldfeder, M.; Fishman, A. Structure–Function correlations in tyrosinases. Protein Sci.; 2015; 24, pp. 1360-1369. [DOI: https://dx.doi.org/10.1002/pro.2734]
3. Nagatsu, T.; Nakashima, A.; Watanabe, H.; Ito, S.; Wakamatsu, K.; Zucca, F.A.; Zecca, L.; Youdim, M.; Wulf, M.; Riederer, P. et al. The role of tyrosine hydroxylase as a key player in neuromelanin synthesis and the association of neuromelanin with Parkinson’s disease. J. Neural Transm.; 2023; 130, pp. 611-625. [DOI: https://dx.doi.org/10.1007/s00702-023-02617-6] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/36939908]
4. Zhao, W.; Yang, A.; Wang, J.; Huang, D.; Deng, Y.; Zhang, X.; Qu, Q.; Ma, W.; Xiong, R.; Zhu, M. et al. Potential application of natural bioactive compounds as skin-whitening agents: A review. J. Cosmet. Dermatol.; 2022; 21, pp. 6669-6687. [DOI: https://dx.doi.org/10.1111/jocd.15437]
5. Li, J.; Feng, L.; Liu, L.; Wang, F.; Ouyang, L.; Zhang, L.; Hu, X.; Wang, G. Recent advances in the design and discovery of synthetic tyrosinase inhibitors. Eur. J. Med. Chem.; 2021; 224, 113744. [DOI: https://dx.doi.org/10.1016/j.ejmech.2021.113744]
6. Peng, Z.; Wang, G.; Zeng, Q.-H.; Li, Y.; Liu, H.; Wang, J.J.; Zhao, Y. A systematic review of synthetic tyrosinase inhibitors and their structure-activity relationship. Crit. Rev. Food Sci. Nutr.; 2022; 62, pp. 4053-4094. [DOI: https://dx.doi.org/10.1080/10408398.2021.1871724] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/33459057]
7. Chib, S.; Jamwal, V.L.; Kumar, V.; Gandhi, S.G.; Saran, S. Fungal production of kojic acid and its industrial applications. Appl. Microbiol. Biotechnol.; 2023; 107, pp. 2111-2130. [DOI: https://dx.doi.org/10.1007/s00253-023-12451-1]
8. Alvarez-Builla, J.; Barluenga, J. Heterocyclic Compounds: An Introduction; John Wiley & Sons, Inc.: Hoboken, NJ, USA, 2011; pp. 1-9.
9. Kabir, E.; Uzzaman, M. A review on biological and medicinal impact of heterocyclic compounds. Results Chem.; 2022; 4, 100606. [DOI: https://dx.doi.org/10.1016/j.rechem.2022.100606]
10. Favi, G. Modern Strategies for Heterocycle Synthesis. Molecules; 2020; 25, 2476. [DOI: https://dx.doi.org/10.3390/molecules25112476]
11. Barreca, M.; Spanò, V.; Raimondi, M.V.; Tarantelli, C.; Spriano, F.; Bertoni, F.; Barraja, P.; Montalbano, A. Recurrence of the oxazole motif in tubulin colchicine site inhibitors with anti-tumor activity. Eur. J. Med. Chem.; 2021; 1, 100004. [DOI: https://dx.doi.org/10.1016/j.ejmcr.2021.100004]
12. Taghour, M.S.; Elkady, H.; Eldehna, W.M.; El-Deeb, N.; Kenawy, A.M.; Elkaeed, E.B.; Alsfouk, B.A.; Alesawy, M.S.; Husein, D.Z.; Metwaly, A.M. Design, synthesis, anti-proliferative evaluation, docking, and MD simulations studies of new thiazolidine-2, 4-diones targeting VEGFR-2 and apoptosis pathway. PLoS ONE; 2022; 17, e0272362. [DOI: https://dx.doi.org/10.1371/journal.pone.0272362] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/36149902]
13. Kotb, A.R.; Bakhotmah, D.A.; Abdallah, A.E.; Elkady, H.; Taghour, M.S.; Eissa, I.H.; El-Zahabi, M.A. Design, synthesis, and biological evaluation of novel bioactive thalidomide analogs as anticancer immunomodulatory agents. RSC Adv.; 2022; 12, pp. 33525-33539. [DOI: https://dx.doi.org/10.1039/D2RA06188K] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/36505721]
14. Zhong, Y.; Qiu, R.-Z.; Sun, S.-L.; Zhao, C.; Fan, T.-Y.; Chen, M.; Li, N.-G.; Shi, Z.-H. Small-molecule fms-like tyrosine kinase 3 inhibitors: An attractive and efficient method for the treatment of acute myeloid leukemia. J. Med. Chem.; 2020; 63, pp. 12403-12428. [DOI: https://dx.doi.org/10.1021/acs.jmedchem.0c00696] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/32659083]
15. Barreca, M.; Ingarra, A.M.; Raimondi, M.V.; Spanò, V.; Piccionello, A.P.; De Franco, M.; Menilli, L.; Gandin, V.; Miolo, G.; Barraja, P. New tricyclic systems as photosensitizers towards triple negative breast cancer cells. Arch. Pharmacal. Res.; 2022; 45, pp. 806-821. [DOI: https://dx.doi.org/10.1007/s12272-022-01414-1]
16. Eissa, I.H.; Dahab, M.A.; Ibrahim, M.K.; Alsaif, N.A.; Alanazi, A.; Eissa, S.I.; Mehany, A.B.; Beauchemin, A.M. Design and discovery of new antiproliferative 1, 2, 4-triazin-3 (2H)-ones as tubulin polymerization inhibitors targeting colchicine binding site. Bioorg. Chem.; 2021; 112, 104965. [DOI: https://dx.doi.org/10.1016/j.bioorg.2021.104965]
17. Gariganti, N.; Loke, S.K.; Pagadala, E.; Chinta, P.; Poola, B.; Chetti, P.; Bansal, A.; Ramachandran, B.; Srinivasadesikan, V.; Kottalanka, R.K. Design, synthesis, anticancer activity of new amide derivatives derived from 1, 2, 3-triazole-benzofuran hybrids: An insights from molecular docking, molecular dynamics simulation and DFT studies. J. Mol. Struct.; 2023; 1273, 134250. [DOI: https://dx.doi.org/10.1016/j.molstruc.2022.134250]
18. Jampilek, J. Heterocycles in medicinal chemistry. Molecules; 2019; 24, 3839. [DOI: https://dx.doi.org/10.3390/molecules24213839]
19. Ismaya, W.T.; Rozeboom, H.J.; Weijn, A.; Mes, J.J.; Fusetti, F.; Wichers, H.J.; Dijkstra, B.W. Crystal Structure of Agaricus bisporus Mushroom Tyrosinase: Identity of the Tetramer Subunits and Interaction with Tropolone. Biochemistry; 2011; 50, pp. 5477-5486. [DOI: https://dx.doi.org/10.1021/bi200395t]
20. Vittorio, S.; Seidel, T.; Germanò, M.P.; Gitto, R.; Ielo, L.; Garon, A.; Rapisarda, A.; Pace, V.; Langer, T.; De Luca, L. A Combination of pharmacophore and docking-based virtual screening to discover new tyrosinase inhibitors. Mol. Inform.; 2020; 39, 1900054. [DOI: https://dx.doi.org/10.1002/minf.201900054]
21. Hu, S.; Laughter, M.R.; Anderson, J.B.; Sadeghpour, M. Emerging topical therapies to treat pigmentary disorders: An evidence-based approach. J. Dermatol. Treat.; 2022; 33, pp. 1931-1937. [DOI: https://dx.doi.org/10.1080/09546634.2021.1940811]
22. Ghani, U. Carbazole and hydrazone derivatives as new competitive inhibitors of tyrosinase: Experimental clues to binuclear copper active site binding. Bioorg. Chem.; 2019; 83, pp. 235-241. [DOI: https://dx.doi.org/10.1016/j.bioorg.2018.10.026] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/30384179]
23. Alizadeh, N.; Hossein Sayahi, M.; Iraji, A.; Yazzaf, R.; Moazzam, A.; Mobaraki, K.; Adib, M.; Attarroshan, M.; Larijani, B.; Rastegar, H. et al. Evaluating the effects of disubstituted 3-hydroxy-1H-pyrrol-2(5H)-one analog as novel tyrosinase inhibitors. Bioorg. Chem.; 2022; 126, 105876. [DOI: https://dx.doi.org/10.1016/j.bioorg.2022.105876] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/35623142]
24. Hu, Y.-G.; Gao, Z.-P.; Zheng, Y.-Y.; Hu, C.-M.; Lin, J.; Wu, X.-Z.; Zhang, X.; Zhou, Y.-S.; Xiong, Z.; Zhu, D.-Y. Synthesis and Biological Activity Evaluation of 2-Cyanopyrrole Derivatives as Potential Tyrosinase Inhibitors. Front. Chem.; 2022; 10, 914944. [DOI: https://dx.doi.org/10.3389/fchem.2022.914944] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/35783205]
25. Iraji, A.; Sheikhi, N.; Attarroshan, M.; Reaz Sharifi Ardani, G.; Kabiri, M.; Naghibi Bafghi, A.; Kobarfard, F.; Rezaei, Z.; Khoshneviszadeh, M.; Foroumadi, A. et al. Design, synthesis, spectroscopic characterization, in vitro tyrosinase inhibition, antioxidant evaluation, in silico and kinetic studies of substituted indole-carbohydrazides. Bioorg. Chem.; 2022; 129, 106140. [DOI: https://dx.doi.org/10.1016/j.bioorg.2022.106140]
26. Yari Boroujeni, S.; Haghighijoo, Z.; Mohammadi-Khanaposhtani, M.; Mosadeghkhah, A.; Moazzam, A.; Yavari, A.; Hajimahmoodi, M.; Sabourian, R.; Hosseini, S.; Larijani, B. Design, Synthesis, in Vitro, and in Silico Evaluation of N-Phenylacetamide-Oxindole-Thiosemicarbazide Hybrids as New Potential Tyrosinase Inhibitors. Chem. Biodivers.; 2022; 19, e202100666. [DOI: https://dx.doi.org/10.1002/cbdv.202100666] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/35156774]
27. Channar, P.A.; Saeed, A.; Larik, F.A.; Batool, B.; Kalsoom, S.; Hasan, M.; Erben, M.F.; El-Seedi, H.R.; Ali, M.; Ashraf, Z. Synthesis of aryl pyrazole via Suzuki coupling reaction, in vitro mushroom tyrosinase enzyme inhibition assay and in silico comparative molecular docking analysis with Kojic acid. Bioorg. Chem.; 2018; 79, pp. 293-300. [DOI: https://dx.doi.org/10.1016/j.bioorg.2018.04.026] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/29793142]
28. Chekir, S.; Debbabi, M.; Regazzetti, A.; Dargère, D.; Laprévote, O.; Jannet, H.B.; Gharbi, R. Design, synthesis and biological evaluation of novel 1, 2, 3-triazole linked coumarinopyrazole conjugates as potent anticholinesterase, anti-5-lipoxygenase, anti-tyrosinase and anti-cancer agents. Bioorg. Chem.; 2018; 80, pp. 189-194. [DOI: https://dx.doi.org/10.1016/j.bioorg.2018.06.005] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/29940340]
29. Li, Q.; Mo, J.; Xiong, B.; Liao, Q.; Chen, Y.; Wang, Y.; Xing, S.; He, S.; Lyu, W.; Zhang, N. et al. Discovery of Resorcinol-Based Polycyclic Structures as Tyrosinase Inhibitors for Treatment of Parkinson’s Disease. ACS Chem. Neurosci.; 2022; 13, pp. 81-96. [DOI: https://dx.doi.org/10.1021/acschemneuro.1c00560]
30. Chai, W.-M.; Yu, Z.-Y.; Lin, M.-Z.; Wei, Q.-M.; Song, S. 5-Methoxy-2-mercaptobenzimidazole as an efficient inhibitor on tyrosinase: Inhibitory activity and mechanism. J. Biosci. Bioeng.; 2021; 131, pp. 356-363. [DOI: https://dx.doi.org/10.1016/j.jbiosc.2020.11.009]
31. Zhou, C.H.; Wang, Y. Recent researches in triazole compounds as medicinal drugs. Curr. Med. Chem.; 2012; 19, pp. 239-280. [DOI: https://dx.doi.org/10.2174/092986712803414213]
32. Matin, M.M.; Matin, P.; Rahman, M.R.; Ben Hadda, T.; Almalki, F.A.; Mahmud, S.; Ghoneim, M.M.; Alruwaily, M.; Alshehri, S. Triazoles and Their Derivatives: Chemistry, Synthesis, and Therapeutic Applications. Front. Mol. Biosci.; 2022; 9, 864286. [DOI: https://dx.doi.org/10.3389/fmolb.2022.864286] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/35547394]
33. Kolb, H.C.; Sharpless, K.B. The growing impact of click chemistry on drug discovery. Drug Discov. Today; 2003; 8, pp. 1128-1137. [DOI: https://dx.doi.org/10.1016/S1359-6446(03)02933-7] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/14678739]
34. Mahdavi, M.; Ashtari, A.; Khoshneviszadeh, M.; Ranjbar, S.; Dehghani, A.; Akbarzadeh, T.; Larijani, B.; Khoshneviszadeh, M.; Saeedi, M. Synthesis of New Benzimidazole-1,2,3-triazole Hybrids as Tyrosinase Inhibitors. Chem. Biodivers.; 2018; 15, e1800120. [DOI: https://dx.doi.org/10.1002/cbdv.201800120]
35. Butt, A.R.S.; Abbasi, M.A.; Rehman, A.U.; Siddiqui, S.Z.; Raza, H.; Hassan, M.; Shah, S.A.A.; Shahid, M.; Seo, S.-Y. Synthesis and structure-activity relationship of tyrosinase inhibiting novel bi-heterocyclic acetamides: Mechanistic insights through enzyme inhibition, kinetics and computational studies. Bioorg. Chem.; 2019; 86, pp. 459-472. [DOI: https://dx.doi.org/10.1016/j.bioorg.2019.01.036] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/30772647]
36. Vanjare, B.D.; Mahajan, P.G.; Dige, N.C.; Raza, H.; Hassan, M.; Han, Y.; Kim, S.J.; Seo, S.-Y.; Lee, K.H. Novel 1,2,4-triazole analogues as mushroom tyrosinase inhibitors: Synthesis, kinetic mechanism, cytotoxicity and computational studies. Mol. Divers.; 2021; 25, pp. 2089-2106. [DOI: https://dx.doi.org/10.1007/s11030-020-10102-5]
37. Bari, A.; Ghani, U.; Ali Syed, S.; Riazullah,. Thiosemicarbazide binds with the dicopper center in the competitive inhibition of mushroom tyrosinase enzyme: Synthesis and molecular modeling of theophylline analogues. Bioorg. Med. Chem.; 2021; 36, 127826. [DOI: https://dx.doi.org/10.1016/j.bmcl.2021.127826] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/33513384]
38. Hałdys, K.; Goldeman, W.; Anger-Góra, N.; Rossowska, J.; Latajka, R. Monosubstituted Acetophenone Thiosemicarbazones as Potent Inhibitors of Tyrosinase: Synthesis, Inhibitory Studies, and Molecular Docking. Pharmaceuticals; 2021; 14, 74. [DOI: https://dx.doi.org/10.3390/ph14010074]
39. Bekier, A.; Węglińska, L.; Paneth, A.; Paneth, P.; Dzitko, K. 4-Arylthiosemicarbazide derivatives as a new class of tyrosinase inhibitors and anti-Toxoplasma gondii agents. J. Enzyme Inhib. Med. Chem.; 2021; 36, pp. 1145-1164. [DOI: https://dx.doi.org/10.1080/14756366.2021.1931164]
40. Cabezudo, I.; Ayelen Ramallo, I.; Alonso, V.L.; Furlan, R.L.E. Effect directed synthesis of a new tyrosinase inhibitor with anti-browning activity. Food Chem.; 2021; 341, 128232. [DOI: https://dx.doi.org/10.1016/j.foodchem.2020.128232]
41. Hosseinpoor, H.; Moghadam Farid, S.; Iraji, A.; Asgari, M.S.; Edraki, N.; Hosseini, S.; Jamshidzadeh, A.; Larijani, B.; Attarroshan, M.; Pirhadi, S. et al. Anti-melanogenesis and anti-tyrosinase properties of aryl-substituted acetamides of phenoxy methyl triazole conjugated with thiosemicarbazide: Design, synthesis and biological evaluations. Bioorg. Chem.; 2021; 114, 104979. [DOI: https://dx.doi.org/10.1016/j.bioorg.2021.104979]
42. Gultekin, E.; Bekircan, O.; Kolcuoğlu, Y.; Akdemir, A. Synthesis of new 1, 2, 4-triazole–(thio) semicarbazide hybrid molecules: Their tyrosinase inhibitor activities and molecular docking analysis. Arch. Pharm.; 2021; 354, 2100058. [DOI: https://dx.doi.org/10.1002/ardp.202100058] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/33900640]
43. Hassan, M.; Vanjare, B.D.; Sim, K.-Y.; Raza, H.; Lee, K.H.; Shahzadi, S.; Kloczkowski, A. Biological and Cheminformatics Studies of Newly Designed Triazole Based Derivatives as Potent Inhibitors against Mushroom Tyrosinase. Molecules; 2022; 27, 1731. [DOI: https://dx.doi.org/10.3390/molecules27051731] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/35268831]
44. Peng, Z.; Wang, G.; Zeng, Q.-H.; Li, Y.; Wu, Y.; Liu, H.; Wang, J.J.; Zhao, Y. Synthesis, antioxidant and anti-tyrosinase activity of 1,2,4-triazole hydrazones as antibrowning agents. Food Chem.; 2021; 341, 128265. [DOI: https://dx.doi.org/10.1016/j.foodchem.2020.128265] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/33031957]
45. Bimoussa, A.; Oubella, A.; Bamou, F.Z.; Khdar, Z.A.; Fawzi, M.; Laamari, Y.; Ait Itto, M.Y.; Morjani, H.; Auhmani, A. New 1, 3, 4-thiadiazoles derivatives: Synthesis, antiproliferative activity, molecular docking and molecular dynamics. Future Med. Chem.; 2022; 14, pp. 881-897. [DOI: https://dx.doi.org/10.4155/fmc-2022-0016]
46. Kim, C.S.; Noh, S.G.; Park, Y.; Kang, D.; Chun, P.; Chung, H.Y.; Jung, H.J.; Moon, H.R. A potent tyrosinase inhibitor,(E)-3-(2,4-Dihydroxyphenyl)-1-(thiophen-2-yl) prop-2-en-1-one, with anti-melanogenesis properties in α-MSH and IBMX-induced B16F10 melanoma cells. Molecules; 2018; 23, 2725. [DOI: https://dx.doi.org/10.3390/molecules23102725]
47. Butt, A.R.S.; Abbasi, M.A.; Siddiqui, S.Z.; Raza, H.; Hassan, M.; Shah, S.A.A.; Seo, S.-Y. Synthesis, Kinetics, Binding Conformations and Structure-activity Relationship of Potent Tyrosinase Inhibitors: Aralkylated 2-aminothiazole-ethyltriazole Hybrids. Iran J. Pharm. Res.; 2021; 20, 206. [DOI: https://dx.doi.org/10.22037/ijpr.2020.15521.13145]
48. Qamar, R.; Saeed, A.; Larik, F.A.; Abbas, Q.; Hassan, M.; Raza, H.; Seo, S.-Y. Novel 1,3-oxazine-tetrazole hybrids as mushroom tyrosinase inhibitors and free radical scavengers: Synthesis, kinetic mechanism, and molecular docking studies. Chem. Biol. Drug Des.; 2019; 93, pp. 123-131. [DOI: https://dx.doi.org/10.1111/cbdd.13352] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/29923689]
49. Barros, M.R.; Menezes, T.M.; da Silva, L.P.; Pires, D.S.; Princival, J.L.; Seabra, G.; Neves, J.L. Furan inhibitory activity against tyrosinase and impact on B16F10 cell toxicity. Int. J. Biol. Macromol.; 2019; 136, pp. 1034-1041. [DOI: https://dx.doi.org/10.1016/j.ijbiomac.2019.06.120]
50. Jung, H.J.; Noh, S.G.; Ryu, I.Y.; Park, C.; Lee, J.Y.; Chun, P.; Moon, H.R.; Chung, H.Y. (E)-1-(Furan-2-yl)-(substituted phenyl)prop-2-en-1-one Derivatives as Tyrosinase Inhibitors and Melanogenesis Inhibition: An In Vitro and In Silico Study. Molecules; 2020; 25, 5460. [DOI: https://dx.doi.org/10.3390/molecules25225460]
51. Pires, D.A.T.; Guedes, I.A.; Pereira, W.L.; Teixeira, R.R.; Dardenne, L.E.; Nascimento, C.J.; Figueroa-Villar, J.D. Isobenzofuran-1(3H)-ones as new tyrosinase inhibitors: Biological activity and interaction studies by molecular docking and NMR. Biochim. Biophys. Acta; 2021; 1869, 140580. [DOI: https://dx.doi.org/10.1016/j.bbapap.2020.140580]
52. Alshaye, N.A.; Mughal, E.U.; Elkaeed, E.B.; Ashraf, Z.; Kehili, S.; Nazir, Y.; Naeem, N.; Abdul Majeed, N.; Sadiq, A. Synthesis and biological evaluation of substituted aurone derivatives as potential tyrosinase inhibitors: In vitro, kinetic, QSAR, docking and drug-likeness studies. J. Biomol. Struct. Dyn.; 2022; pp. 1-16. [DOI: https://dx.doi.org/10.1080/07391102.2022.2132296] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/36255179]
53. Kim, S.J.; Yang, J.; Lee, S.; Park, C.; Kang, D.; Akter, J.; Ullah, S.; Kim, Y.-J.; Chun, P.; Moon, H.R. The tyrosinase inhibitory effects of isoxazolone derivatives with a (Z)-β-phenyl-α, β-unsaturated carbonyl scaffold. Bioorg. Med. Chem.; 2018; 26, pp. 3882-3889. [DOI: https://dx.doi.org/10.1016/j.bmc.2018.05.047]
54. Olanipekun, B.E.; Ponnapalli, M.G.; Patel, H.K.; Munipalle, K.; Shaik, K. Design, synthesis of new phenyl acetylene and isoxazole analogues of arjunolic acid as potent tyrosinase and alpha glucosidase inhibitors. Nat. Prod. Res.; 2021; 37, pp. 1092-1097. [DOI: https://dx.doi.org/10.1080/14786419.2021.1986817] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/34625004]
55. Olanipekun, B.E.; Ponnapalli, M.G.; Shaik, K.; Nanubolu, J.B.; Kommalapati, V.K.; Tangutur, A.D. α-Glucosidase inhibitory isomeric corniculatolides from the stems of the indian mangrove plant, Xylocarpus granatum. J. Nat. Prod.; 2020; 83, pp. 20-25. [DOI: https://dx.doi.org/10.1021/acs.jnatprod.9b00414] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/31895570]
56. Choi, I.; Park, Y.; Ryu, I.Y.; Jung, H.J.; Ullah, S.; Choi, H.; Park, C.; Kang, D.; Lee, S.; Chun, P. et al. In silico and in vitro insights into tyrosinase inhibitors with a 2-thioxooxazoline-4-one template. Comput. Struct. Biotechnol. J.; 2021; 19, pp. 37-50. [DOI: https://dx.doi.org/10.1016/j.csbj.2020.12.001] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/33363708]
57. Vanjare, B.D.; Choi, N.G.; Mahajan, P.G.; Raza, H.; Hassan, M.; Han, Y.; Yu, S.-M.; Kim, S.J.; Seo, S.-Y.; Lee, K.H. Novel 1,3,4-oxadiazole compounds inhibit the tyrosinase and melanin level: Synthesis, in-vitro, and in-silico studies. Bioorg. Med. Chem.; 2021; 41, 116222. [DOI: https://dx.doi.org/10.1016/j.bmc.2021.116222] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/34058664]
58. Raza, H.; Rehman Sadiq Butt, A.; Athar Abbasi, M.; Zahra Siddiqui, S.; Hassan, M.; Adnan Ali Shah, S.; Ja Kim, S. 2-Aminothiazole-Oxadiazole Bearing N-Arylated Butanamides: Convergent Synthesis, Tyrosinase Inhibition, Kinetics, Structure-Activity Relationship, and Binding Conformations. Chem. Biodivers.; 2023; 20, e202201019. [DOI: https://dx.doi.org/10.1002/cbdv.202201019]
59. Karakaya, G.; Türe, A.; Ercan, A.; Öncül, S.; Aytemir, M.D. Synthesis, computational molecular docking analysis and effectiveness on tyrosinase inhibition of kojic acid derivatives. Bioorg. Chem.; 2019; 88, 102950. [DOI: https://dx.doi.org/10.1016/j.bioorg.2019.102950]
60. Rezaei, M.; Mohammadi, H.T.; Mahdavi, A.; Shourian, M.; Ghafouri, H. Evaluation of thiazolidinone derivatives as a new class of mushroom tyrosinase inhibitors. Int. J. Biol. Macromol.; 2018; 108, pp. 205-213. [DOI: https://dx.doi.org/10.1016/j.ijbiomac.2017.11.147]
61. Bang, E.; Lee, E.K.; Noh, S.G.; Jung, H.J.; Moon, K.M.; Park, M.H.; Park, Y.J.; Hyun, M.K.; Lee, A.K.; Kim, S.J. In vitro and in vivo evidence of tyrosinase inhibitory activity of a synthesized (Z)-5-(3-hydroxy-4-methoxybenzylidene)-2-thioxothiazolidin-4-one (5-HMT). Exp. Dermatol.; 2019; 28, pp. 734-737. [DOI: https://dx.doi.org/10.1111/exd.13863]
62. Piechowska, K.; Świtalska, M.; Cytarska, J.; Jaroch, K.; Łuczykowski, K.; Chałupka, J.; Wietrzyk, J.; Misiura, K.; Bojko, B.; Kruszewski, S. Discovery of tropinone-thiazole derivatives as potent caspase 3/7 activators, and noncompetitive tyrosinase inhibitors with high antiproliferative activity: Rational design, one-pot tricomponent synthesis, and lipophilicity determination. Eur. J. Med. Chem.; 2019; 175, pp. 162-171. [DOI: https://dx.doi.org/10.1016/j.ejmech.2019.05.006] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/31082763]
63. Piechowska, K.; Mizerska-Kowalska, M.; Zdzisińska, B.; Cytarska, J.; Baranowska-Łączkowska, A.; Jaroch, K.; Łuczykowski, K.; Płaziński, W.; Bojko, B.; Kruszewski, S. Tropinone-derived alkaloids as potent anticancer agents: Synthesis, tyrosinase inhibition, mechanism of action, DFT calculation, and molecular docking studies. Int. J. Mol. Sci.; 2020; 21, 9050. [DOI: https://dx.doi.org/10.3390/ijms21239050] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/33260768]
64. Ujan, R.; Saeed, A.; Ashraf, S.; Channar, P.A.; Abbas, Q.; Rind, M.A.; Hassan, M.; Raza, H.; Seo, S.-Y.; El-Seedi, H.R. Synthesis, computational studies and enzyme inhibitory kinetics of benzothiazole-linked thioureas as mushroom tyrosinase inhibitors. J. Biomol. Struct. Dyn.; 2021; 39, pp. 7035-7043. [DOI: https://dx.doi.org/10.1080/07391102.2020.1804459]
65. Ha, Y.M.; Park, Y.J.; Kim, J.-A.; Park, D.; Park, J.Y.; Lee, H.J.; Lee, J.Y.; Moon, H.R.; Chung, H.Y. Design and synthesis of 5-(substituted benzylidene) thiazolidine-2, 4-dione derivatives as novel tyrosinase inhibitors. Eur. J. Med. Chem.; 2012; 49, pp. 245-252. [DOI: https://dx.doi.org/10.1016/j.ejmech.2012.01.019] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/22301213]
66. Ha, Y.M.; Park, J.Y.; Park, Y.J.; Park, D.; Choi, Y.J.; Kim, J.M.; Lee, E.K.; Han, Y.K.; Kim, J.-A.; Lee, J.Y. Synthesis and biological activity of hydroxy substituted phenyl-benzo [d] thiazole analogues for antityrosinase activity in B16 cells. Bioorg. Med. Chem.; 2011; 21, pp. 2445-2449. [DOI: https://dx.doi.org/10.1016/j.bmcl.2011.02.064] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/21397499]
67. Bang, E.; Noh, S.-G.; Ha, S.; Jung, H.J.; Kim, D.H.; Lee, A.K.; Hyun, M.K.; Kang, D.; Lee, S.; Park, C. Evaluation of the novel synthetic tyrosinase inhibitor (Z)-3-(3-bromo-4-hydroxybenzylidene) thiochroman-4-one (MHY1498) in vitro and in silico. Molecules; 2018; 23, 3307. [DOI: https://dx.doi.org/10.3390/molecules23123307]
68. Choi, H.; Ryu, I.Y.; Choi, I.; Ullah, S.; Jung, H.J.; Park, Y.; Jeong, Y.; Hwang, Y.; Hong, S.; Yoon, I.-S. et al. Novel Anti-Melanogenic Compounds, (Z)-5-(Substituted Benzylidene)-4-thioxothiazolidin-2-one Derivatives: In Vitro and In Silico Insights. Molecules; 2021; 26, 4963. [DOI: https://dx.doi.org/10.3390/molecules26164963]
69. Jeong, Y.; Hong, S.; Jung, H.J.; Ullah, S.; Hwang, Y.; Choi, H.; Ko, J.; Lee, J.; Chun, P.; Chung, H.Y. et al. Identification of a Novel Class of Anti-Melanogenic Compounds, (Z)-5-(Substituted benzylidene)-3-phenyl-2-thioxothiazolidin-4-one Derivatives, and Their Reactive Oxygen Species Scavenging Activities. Antioxidants; 2022; 11, 948. [DOI: https://dx.doi.org/10.3390/antiox11050948]
70. Hwang, Y.; Lee, J.; Jung, H.J.; Ullah, S.; Ko, J.; Jeong, Y.; Park, Y.J.; Kang, M.K.; Yun, H.; Kim, M.-S. et al. A Novel Class of Potent Anti-Tyrosinase Compounds with Antioxidant Activity, 2-(Substituted phenyl)-5-(trifluoromethyl)benzo[d]thiazoles: In Vitro and In Silico Insights. Antioxidants; 2022; 11, 1375. [DOI: https://dx.doi.org/10.3390/antiox11071375]
71. Choi, H.; Ryu, I.Y.; Choi, I.; Ullah, S.; Jung, H.J.; Park, Y.; Hwang, Y.; Jeong, Y.; Hong, S.; Chun, P. et al. Identification of (Z)-2-benzylidene-dihydroimidazothiazolone derivatives as tyrosinase inhibitors: Anti-melanogenic effects and in silico studies. Comput. Struct. Biotechnol. J.; 2022; 20, pp. 899-912. [DOI: https://dx.doi.org/10.1016/j.csbj.2022.02.007]
72. Lee, J.; Park, Y.J.; Jung, H.J.; Ullah, S.; Yoon, D.; Jeong, Y.; Kim, G.Y.; Kang, M.K.; Kang, D.; Park, Y. et al. Design and Synthesis of (Z)-2-(Benzylamino)-5-benzylidenethiazol-4(5H)-one Derivatives as Tyrosinase Inhibitors and Their Anti-Melanogenic and Antioxidant Effects. Molecules; 2023; 28, 848. [DOI: https://dx.doi.org/10.3390/molecules28020848] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/36677908]
73. Shehzadi, S.A.; Saeed, A.; Perveen, F.; Channar, P.A.; Arshad, I.; Abbas, Q.; Kalsoom, S.; Yousaf, S.; Simpson, J. Identification of two novel thiazolidin-2-imines as tyrosinase inhibitors: Synthesis, crystal structure, molecular docking and DFT studies. Heliyon; 2022; 8, e10098. [DOI: https://dx.doi.org/10.1016/j.heliyon.2022.e10098] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/36046526]
74. Li, D.-F.; Hu, P.-P.; Liu, M.-S.; Kong, X.-L.; Zhang, J.-C.; Hider, R.C.; Zhou, T. Design and synthesis of hydroxypyridinone-L-phenylalanine conjugates as potential tyrosinase inhibitors. J. Agric. Food Chem.; 2013; 61, pp. 6597-6603. [DOI: https://dx.doi.org/10.1021/jf401585f] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/23802151]
75. Zhao, D.-Y.; Zhang, M.-X.; Dong, X.-W.; Hu, Y.-Z.; Dai, X.-Y.; Wei, X.; Hider, R.C.; Zhang, J.-C.; Zhou, T. Design and synthesis of novel hydroxypyridinone derivatives as potential tyrosinase inhibitors. Bioorg. Med. Chem.; 2016; 26, pp. 3103-3108. [DOI: https://dx.doi.org/10.1016/j.bmcl.2016.05.006]
76. Shao, L.-L.; Wang, X.-L.; Chen, K.; Dong, X.-W.; Kong, L.-M.; Zhao, D.-Y.; Hider, R.C.; Zhou, T. Novel hydroxypyridinone derivatives containing an oxime ether moiety: Synthesis, inhibition on mushroom tyrosinase and application in anti-browning of fresh-cut apples. Food Chem.; 2018; 242, pp. 174-181. [DOI: https://dx.doi.org/10.1016/j.foodchem.2017.09.054]
77. Jun, N.; Hong, G.; Jun, K. Synthesis and evaluation of 2′,4′,6′-trihydroxychalcones as a new class of tyrosinase inhibitors. Bioorg. Med. Chem.; 2007; 15, pp. 2396-2402. [DOI: https://dx.doi.org/10.1016/j.bmc.2007.01.017]
78. Nerya, O.; Musa, R.; Khatib, S.; Tamir, S.; Vaya, J. Chalcones as potent tyrosinase inhibitors: The effect of hydroxyl positions and numbers. Phytochemistry; 2004; 65, pp. 1389-1395. [DOI: https://dx.doi.org/10.1016/j.phytochem.2004.04.016]
79. Zhu, Y.-Z.; Chen, K.; Chen, Y.-L.; Zhang, C.; Xie, Y.-Y.; Hider, R.C.; Zhou, T. Design and synthesis of novel stilbene-hydroxypyridinone hybrids as tyrosinase inhibitors and their application in the anti-browning of freshly-cut apples. Food Chem.; 2022; 385, 132730. [DOI: https://dx.doi.org/10.1016/j.foodchem.2022.132730]
80. Ullah, S.; Kang, D.; Lee, S.; Ikram, M.; Park, C.; Park, Y.; Yoon, S.; Chun, P.; Moon, H.R. Synthesis of cinnamic amide derivatives and their anti-melanogenic effect in α-MSH-stimulated B16F10 melanoma cells. Eur. J. Med. Chem.; 2019; 161, pp. 78-92. [DOI: https://dx.doi.org/10.1016/j.ejmech.2018.10.025]
81. Lapasam, A.; Kollipara, M.R. A survey of crystal structures and biological activities of platinum group metal complexes containing N-acylthiourea ligands. Phosphorus Sulfur Silicon Relat. Elem.; 2020; 195, pp. 779-804. [DOI: https://dx.doi.org/10.1080/10426507.2020.1764956]
82. Noori, M.; Sabourian, R.; Tasharoie, A.; Safavi, M.; Iraji, A.; Khalili Ghomi, M.; Dastyafteh, N.; Irajie, C.; Zarenezhad, E.; Mostafavi Pour, S.M. Thioquinoline derivatives conjugated to thiosemicarbazide as potent tyrosinase inhibitors with anti-melanogenesis properties. Sci. Rep.; 2023; 13, 2578. [DOI: https://dx.doi.org/10.1038/s41598-023-28852-1]
83. Larik, F.A.; Saeed, A.; Channar, P.A.; Muqadar, U.; Abbas, Q.; Hassan, M.; Seo, S.-Y.; Bolte, M. Design, synthesis, kinetic mechanism and molecular docking studies of novel 1-pentanoyl-3-arylthioureas as inhibitors of mushroom tyrosinase and free radical scavengers. Eur. J. Med. Chem.; 2017; 141, pp. 273-281. [DOI: https://dx.doi.org/10.1016/j.ejmech.2017.09.059] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/29040952]
84. Mustafa, M.N.; Saeed, A.; Channar, P.A.; Larik, F.A.; Zain-ul abideen, M.; Shabir, G.; Abbas, Q.; Hassan, M.; Raza, H.; Seo, S.-Y. Synthesis, molecular docking and kinetic studies of novel quinolinyl based acyl thioureas as mushroom tyrosinase inhibitors and free radical scavengers. Bioorg. Chem.; 2019; 90, 103063. [DOI: https://dx.doi.org/10.1016/j.bioorg.2019.103063] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/31220666]
85. Mirmortazavi, S.S.; Farvandi, M.; Ghafouri, H.; Mohammadi, A.; Shourian, M. Evaluation of novel pyrimidine derivatives as a new class of mushroom tyrosinase inhibitor. Drug Des. Devel. Ther.; 2019; 13, pp. 2169-2178. [DOI: https://dx.doi.org/10.2147/DDDT.S209324]
86. Debbabi, M.; Nimbarte, V.D.; Chekir, S.; Chortani, S.; Romdhane, A.; Ben Jannet, H. Design and synthesis of novel potent anticoagulant and anti-tyrosinase pyranopyrimidines and pyranotriazolopyrimidines: Insights from molecular docking and SAR analysis. Bioorg. Chem.; 2019; 82, pp. 129-138. [DOI: https://dx.doi.org/10.1016/j.bioorg.2018.10.004] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/30312868]
87. Saeed, A.; Ejaz, S.A.; Khalid, A.; Channar, P.A.; Aziz, M.; Abbas, Q.; Wani, T.A.; Alsaif, N.A.; Alanazi, M.M.; Al-Hossaini, A.M. et al. Acetophenone-Based 3,4-Dihydropyrimidine-2(1H)-Thione as Potential Inhibitor of Tyrosinase and Ribonucleotide Reductase: Facile Synthesis, Crystal Structure, In-Vitro and In-Silico Investigations. Int. J. Mol. Sci.; 2022; 23, 13164. [DOI: https://dx.doi.org/10.3390/ijms232113164]
88. Chiriapkin, A.; Kodonidi, I.; Pozdnyakov, D. Targeted Synthesis and Study of Anti-tyrosinase Activity of 2-Substituted Tetrahydrobenzo[4,5]Thieno[2,3-d]Pyrimidine-4(3H)-One. Iran J. Pharm. Res.; 2022; 21, e126557. [DOI: https://dx.doi.org/10.5812/ijpr-126557]
89. Dige, N.C.; Mahajan, P.G.; Raza, H.; Hassan, M.; Vanjare, B.D.; Hong, H.; Hwan Lee, K.; Latip, J.; Seo, S.-Y. Ultrasound mediated efficient synthesis of new 4-oxoquinazolin-3(4H)-yl)furan-2-carboxamides as potent tyrosinase inhibitors: Mechanistic approach through chemoinformatics and molecular docking studies. Bioorg. Chem.; 2019; 92, 103201. [DOI: https://dx.doi.org/10.1016/j.bioorg.2019.103201]
90. Ferro, S.; Deri, B.; Germanò, M.P.; Gitto, R.; Ielo, L.; Buemi, M.R.; Certo, G.; Vittorio, S.; Rapisarda, A.; Pazy, Y. Targeting tyrosinase: Development and structural insights of novel inhibitors bearing arylpiperidine and arylpiperazine fragments. J. Med. Chem.; 2018; 61, pp. 3908-3917. [DOI: https://dx.doi.org/10.1021/acs.jmedchem.7b01745]
91. Ielo, L.; Deri, B.; Germano, M.P.; Vittorio, S.; Mirabile, S.; Gitto, R.; Rapisarda, A.; Ronsisvalle, S.; Floris, S.; Pazy, Y. Exploiting the 1-(4-fluorobenzyl) piperazine fragment for the development of novel tyrosinase inhibitors as anti-melanogenic agents: Design, synthesis, structural insights and biological profile. Eur. J. Med. Chem.; 2019; 178, pp. 380-389. [DOI: https://dx.doi.org/10.1016/j.ejmech.2019.06.019]
92. Vittorio, S.; Ielo, L.; Mirabile, S.; Gitto, R.; Fais, A.; Floris, S.; Rapisarda, A.; Germanò, M.P.; De Luca, L. 4-Fluorobenzylpiperazine-containing derivatives as efficient inhibitors of mushroom tyrosinase. ChemMedChem; 2020; 15, pp. 1757-1764. [DOI: https://dx.doi.org/10.1002/cmdc.202000125] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/32692882]
93. Mirabile, S.; Vittorio, S.; Paola Germanò, M.; Adornato, I.; Ielo, L.; Rapisarda, A.; Gitto, R.; Pintus, F.; Fais, A.; De Luca, L. Evaluation of 4-(4-Fluorobenzyl)piperazin-1-yl]-Based Compounds as Competitive Tyrosinase Inhibitors Endowed with Antimelanogenic Effects. ChemMedChem; 2021; 16, pp. 3083-3093. [DOI: https://dx.doi.org/10.1002/cmdc.202100396] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/34223697]
94. Abbasi, M.A.; Rehman, Z.U.; Rehman, A.U.; Siddiqui, S.Z.; Nazir, M.; Hassan, M.; Raza, H.; Shah, S.A.A. Synthesis of bi-heterocyclic sulfonamides as tyrosinase inhibitors: Lineweaver–Burk plot evaluation and computational ascriptions. Acta Chim. Slov.; 2020; 67, pp. 403-414. [DOI: https://dx.doi.org/10.17344/acsi.2019.5283]
95. De Luca, L.; Germanò, M.P.; Fais, A.; Pintus, F.; Buemi, M.R.; Vittorio, S.; Mirabile, S.; Rapisarda, A.; Gitto, R. Discovery of a new potent inhibitor of mushroom tyrosinase (Agaricus bisporus) containing 4-(4-hydroxyphenyl) piperazin-1-yl moiety. Bioorg. Med. Chem.; 2020; 28, 115497. [DOI: https://dx.doi.org/10.1016/j.bmc.2020.115497] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/32312487]
96. Mirabile, S.; Germanò, M.P.; Fais, A.; Lombardo, L.; Ricci, F.; Floris, S.; Cacciola, A.; Rapisarda, A.; Gitto, R.; De Luca, L. Design, Synthesis, and in Vitro Evaluation of 4-(4-Hydroxyphenyl)piperazine-Based Compounds Targeting Tyrosinase. ChemMedChem; 2022; 17, e202200305. [DOI: https://dx.doi.org/10.1002/cmdc.202200305] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/36093940]
97. Raza, H.; Abbasi, M.A.; Siddiqui, S.Z.; Hassan, M.; Abbas, Q.; Hong, H.; Shah, S.A.A.; Shahid, M.; Seo, S.-Y. Synthesis, molecular docking, dynamic simulations, kinetic mechanism, cytotoxicity evaluation of N-(substituted-phenyl)-4-{(4-[(E)-3-phenyl-2-propenyl]-1-piperazinyl} butanamides as tyrosinase and melanin inhibitors: In vitro, in vivo and in silico approaches. Bioorg. Chem.; 2020; 94, 103445. [DOI: https://dx.doi.org/10.1016/j.bioorg.2019.103445]
98. Romagnoli, R.; Oliva, P.; Prencipe, F.; Manfredini, S.; Germanò, M.P.; De Luca, L.; Ricci, F.; Corallo, D.; Aveic, S.; Mariotto, E. et al. Cinnamic acid derivatives linked to arylpiperazines as novel potent inhibitors of tyrosinase activity and melanin synthesis. Eur. J. Med. Chem.; 2022; 231, 114147. [DOI: https://dx.doi.org/10.1016/j.ejmech.2022.114147]
99. Hajimiri, M.; Khosravikia, M.; Khoshneviszadeh, M.; Pedrood, K.; Hosseini, S.Z.; Asgari, M.S.; Pirhadi, S.; Attarroshan, M.; Mobaraki, K.; Hosseini, S. Rational Design, Synthesis, in Vitro, and in Silico Studies of Chlorophenylquinazolin-4 (3H)-One Containing Different Aryl Acetohydrazides as Tyrosinase Inhibitors. Chem. Biodivers.; 2022; 19, e202100964. [DOI: https://dx.doi.org/10.1002/cbdv.202100964]
100. Huang, Y.; Yang, J.; Chi, Y.; Gong, C.; Yang, H.; Zeng, F.; Gao, F.; Hua, X.; Wang, Z. Newly Designed Quinazolinone Derivatives as Novel Tyrosinase Inhibitor: Synthesis, Inhibitory Activity, and Mechanism. Molecules; 2022; 27, 5558. [DOI: https://dx.doi.org/10.3390/molecules27175558]
101. Shi, Y.; Chen, Q.-X.; Wang, Q.; Song, K.-K.; Qiu, L. Inhibitory effects of cinnamic acid and its derivatives on the diphenolase activity of mushroom (Agaricus bisporus) tyrosinase. Food Chem.; 2005; 92, pp. 707-712. [DOI: https://dx.doi.org/10.1016/j.foodchem.2004.08.031]
102. Lim, J.Y.; Ishiguro, K.; Kubo, I. Tyrosinase inhibitory p-Coumaric acid from Ginseng leaves. Phytother. Res.; 1999; 13, pp. 371-375. [DOI: https://dx.doi.org/10.1002/(SICI)1099-1573(199908/09)13:5<371::AID-PTR453>3.0.CO;2-L]
103. Lee, H.-S. Tyrosinase inhibitors of Pulsatilla cernua root-derived materials. J. Agric. Food Chem.; 2002; 50, pp. 1400-1403. [DOI: https://dx.doi.org/10.1021/jf011230f] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/11879010]
104. Ullah, S.; Park, Y.; Ikram, M.; Lee, S.; Park, C.; Kang, D.; Yang, J.; Akter, J.; Yoon, S.; Chun, P. Design, synthesis and anti-melanogenic effect of cinnamamide derivatives. Bioorg. Med. Chem.; 2018; 26, pp. 5672-5681. [DOI: https://dx.doi.org/10.1016/j.bmc.2018.10.014] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/30366788]
105. Ullah, S.; Park, C.; Ikram, M.; Kang, D.; Lee, S.; Yang, J.; Park, Y.; Yoon, S.; Chun, P.; Moon, H.R. Tyrosinase inhibition and anti-melanin generation effect of cinnamamide analogues. Bioorg. Chem.; 2019; 87, pp. 43-55. [DOI: https://dx.doi.org/10.1016/j.bioorg.2019.03.001] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/30856375]
106. Ghafary, S.; Ranjbar, S.; Larijani, B.; Amini, M.; Biglar, M.; Mahdavi, M.; Bakhshaei, M.; Khoshneviszadeh, M.; Sakhteman, A.; Khoshneviszadeh, M. Novel morpholine containing cinnamoyl amides as potent tyrosinase inhibitors. Int. J. Biol. Macromol.; 2019; 135, pp. 978-985. [DOI: https://dx.doi.org/10.1016/j.ijbiomac.2019.05.201] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/31150673]
107. Okajima, S.; Hamamoto, A.; Asano, M.; Isogawa, K.; Ito, H.; Kato, S.; Hirata, Y.; Furuta, K.; Takemori, H. Azepine derivative T4FAT, a new copper chelator, inhibits tyrosinase. Biochem. Biophys. Res. Commun.; 2019; 509, pp. 209-215. [DOI: https://dx.doi.org/10.1016/j.bbrc.2018.12.105]
108. Choi, M.-H.; Yang, S.-H.; Kim, D.-S.; Kim, N.D.; Shin, H.-J.; Liu, K. Novel Quercetin Derivative of 3,7-Dioleylquercetin Shows Less Toxicity and Highly Potent Tyrosinase Inhibition Activity. Int. J. Mol. Sci.; 2021; 22, 4264. [DOI: https://dx.doi.org/10.3390/ijms22084264]
109. Karimian, S.; Ranjbar, S.; Dadfar, M.; Khoshneviszadeh, M.; Gholampour, M.; Sakhteman, A.; Khoshneviszadeh, M. 4 H-benzochromene derivatives as novel tyrosinase inhibitors and radical scavengers: Synthesis, biological evaluation, and molecular docking analysis. Mol. Divers.; 2021; 25, pp. 2339-2349. [DOI: https://dx.doi.org/10.1007/s11030-020-10123-0]
110. Ashraf, J.; Mughal, E.U.; Sadiq, A.; Bibi, M.; Naeem, N.; Ali, A.; Massadaq, A.; Fatima, N.; Javid, A.; Zafar, M.N. et al. Exploring 3-hydroxyflavone scaffolds as mushroom tyrosinase inhibitors: Synthesis, X-ray crystallography, antimicrobial, fluorescence behaviour, structure-activity relationship and molecular modelling studies. J. Biomol. Struct. Dyn.; 2021; 39, pp. 7107-7122. [DOI: https://dx.doi.org/10.1080/07391102.2020.1805364]
111. Ashraf, J.; Mughal, E.U.; Alsantali, R.I.; Obaid, R.J.; Sadiq, A.; Naeem, N.; Ali, A.; Massadaq, A.; Javed, Q.; Javid, A. et al. Structure-based designing and synthesis of 2-phenylchromone derivatives as potent tyrosinase inhibitors: In vitro and in silico studies. Bioorg. Med. Chem.; 2021; 35, 116057. [DOI: https://dx.doi.org/10.1016/j.bmc.2021.116057]
112. Mughal, E.U.; Ashraf, J.; Hussein, E.M.; Nazir, Y.; Alwuthaynani, A.S.; Naeem, N.; Sadiq, A.; Alsantali, R.I.; Ahmed, S.A. Design, Synthesis, and Structural Characterization of Thioflavones and Thioflavonols as Potential Tyrosinase Inhibitors: In Vitro and In Silico Studies. ACS Omega; 2022; 7, pp. 17444-17461. [DOI: https://dx.doi.org/10.1021/acsomega.2c01841] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/35647459]
113. Shagufta,; Ahmad, I. Recent insight into the biological activities of synthetic xanthone derivatives. Eur. J. Med. Chem.; 2016; 116, pp. 267-280. [DOI: https://dx.doi.org/10.1016/j.ejmech.2016.03.058] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/27111599]
114. Yu, L.; Chen, L.; Luo, G.; Liu, L.; Zhu, W.; Yan, P.; Zhang, P.; Zhang, C.; Wu, W. Study on synthesis and biological evaluation of 3-aryl substituted xanthone derivatives as novel and potent tyrosinase inhibitors. Chem. Pharm. Bull.; 2019; 67, pp. 1232-1241. [DOI: https://dx.doi.org/10.1248/cpb.c19-00572] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/31495804]
115. Resende, D.I.; Almeida, M.C.; Maciel, B.; Carmo, H.; Sousa Lobo, J.; Dal Pozzo, C.; Cravo, S.M.; Rosa, G.P.; Kane-Pagès, A.; do Carmo Barreto, M. Efficacy, stability, and safety evaluation of new polyphenolic xanthones towards identification of bioactive compounds to fight skin photoaging. Molecules; 2020; 25, 2782. [DOI: https://dx.doi.org/10.3390/molecules25122782]
116. Rosa, G.P.; Palmeira, A.; Resende, D.I.S.P.; Almeida, I.F.; Kane-Pagès, A.; Barreto, M.C.; Sousa, E.; Pinto, M.M.M. Xanthones for melanogenesis inhibition: Molecular docking and QSAR studies to understand their anti-tyrosinase activity. Bioorg. Med. Chem.; 2021; 29, 115873. [DOI: https://dx.doi.org/10.1016/j.bmc.2020.115873]
117. Roh, E.-J. Inhibitory Effects of Coumarin Derivatives on Tyrosinase. Molecules; 2021; 26, 2346. [DOI: https://dx.doi.org/10.3390/molecules26082346]
118. Pintus, F.; Floris, S.; Fais, A.; Era, B.; Kumar, A.; Gatto, G.; Uriarte, E.; Matos, M.J. Hydroxy-3-Phenylcoumarins as Multitarget Compounds for Skin Aging Diseases: Synthesis, Molecular Docking and Tyrosinase, Elastase, Collagenase and Hyaluronidase Inhibition, and Sun Protection Factor. Molecules; 2022; 27, 6914. [DOI: https://dx.doi.org/10.3390/molecules27206914]
119. Masuri, S.; Era, B.; Pintus, F.; Cadoni, E.; Cabiddu, M.G.; Fais, A.; Pivetta, T. Hydroxylated Coumarin-Based Thiosemicarbazones as Dual Antityrosinase and Antioxidant Agents. Int. J. Mol. Sci.; 2023; 24, 1678. [DOI: https://dx.doi.org/10.3390/ijms24021678]
120. Nasab, N.H.; Raza, H.; Eom, Y.S.; Hassan, M.; Kloczkowski, A.; Kim, S.J. Synthesis and discovery of potential tyrosinase inhibitor of new coumarin-based thiophenyl-pyrazolylthiazole nuclei: In-vitro evaluation, cytotoxicity, kinetic and computational studies. Chem. Biol. Drug Des.; 2023; 101, pp. 1262-1272. [DOI: https://dx.doi.org/10.1111/cbdd.14209]
121. Wang, W.; Gao, Y.; Wang, W.; Zhang, J.; Yin, J.; Le, T.; Xue, J.; Engelhardt, U.H.; Jiang, H. Kojic Acid Showed Consistent Inhibitory Activity on Tyrosinase from Mushroom and in Cultured B16F10 Cells Compared with Arbutins. Antioxidants; 2022; 11, 502. [DOI: https://dx.doi.org/10.3390/antiox11030502]
122. Chang, T.-S. An Updated Review of Tyrosinase Inhibitors. Int. J. Mol. Sci.; 2009; 10, pp. 2440-2475. [DOI: https://dx.doi.org/10.3390/ijms10062440]
123. Monteiro, R.; Kishore, B.; Bhat, R.; Sukumar, D.; Martis, J.; Ganesh, H. A comparative study of the efficacy of 4% hydroquinone vs 0.75% Kojic acid cream in the treatment of facial melasma. Indian J. Dermatol.; 2013; 58, 157. [DOI: https://dx.doi.org/10.4103/0019-5154.108070] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/23716817]
124. Noh, J.-M.; Kwak, S.-Y.; Kim, D.-H.; Lee, Y.-S. Kojic acid–tripeptide amide as a new tyrosinase inhibitor. Peptide Sci.; 2007; 88, pp. 300-307. [DOI: https://dx.doi.org/10.1002/bip.20670] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/17211869]
125. Yousefnejad, F.; Iraji, A.; Sabourian, R.; Moazzam, A.; Tasharoie, S.; Sara Mirfazli, S.; Zomorodian, K.; Alireza Akhlagh, S.; Hosseini, S.; Larijani, B. Ugi Bis-Amide Derivatives as Tyrosinase Inhibitor; Synthesis, Biology Assessment, and in Silico Analysis. Chem. Biodivers.; 2023; 20, e202200607. [DOI: https://dx.doi.org/10.1002/cbdv.202200607] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/36538729]
126. Chen, Y.-M.; Su, W.-C.; Li, C.; Shi, Y.; Chen, Q.-X.; Zheng, J.; Tang, D.-L.; Chen, S.-M.; Wang, Q. Anti-melanogenesis of novel kojic acid derivatives in B16F10 cells and zebrafish. Int. J. Biol. Macromol.; 2019; 123, pp. 723-731. [DOI: https://dx.doi.org/10.1016/j.ijbiomac.2018.11.031]
127. Chen, Y.-M.; Li, C.; Zhang, W.-J.; Shi, Y.; Wen, Z.-J.; Chen, Q.-X.; Wang, Q. Kinetic and computational molecular docking simulation study of novel kojic acid derivatives as anti-tyrosinase and antioxidant agents. J. Enzyme Inhib. Med. Chem.; 2019; 34, pp. 990-998. [DOI: https://dx.doi.org/10.1080/14756366.2019.1609467] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/31072148]
128. Ashooriha, M.; Khoshneviszadeh, M.; Khoshneviszadeh, M.; Moradi, S.E.; Rafiei, A.; Kardan, M.; Emami, S. 1, 2, 3-Triazole-based kojic acid analogs as potent tyrosinase inhibitors: Design, synthesis and biological evaluation. Bioorg. Chem.; 2019; 82, pp. 414-422. [DOI: https://dx.doi.org/10.1016/j.bioorg.2018.10.069]
129. Ashooriha, M.; Khoshneviszadeh, M.; Khoshneviszadeh, M.; Rafiei, A.; Kardan, M.; Yazdian-Robati, R.; Emami, S. Kojic acid–natural product conjugates as mushroom tyrosinase inhibitors. Eur. J. Med. Chem.; 2020; 201, 112480. [DOI: https://dx.doi.org/10.1016/j.ejmech.2020.112480]
130. Sepehri, N.; Iraji, A.; Yavari, A.; Asgari, M.S.; Zamani, S.; Hosseini, S.; Bahadorikhalili, S.; Pirhadi, S.; Larijani, B.; Khoshneviszadeh, M. et al. The natural-based optimization of kojic acid conjugated to different thio-quinazolinones as potential anti-melanogenesis agents with tyrosinase inhibitory activity. Bioorg. Med. Chem.; 2021; 36, 116044. [DOI: https://dx.doi.org/10.1016/j.bmc.2021.116044]
131. Wang, G.; He, M.; Huang, Y.; Peng, Z. Synthesis and biological evaluation of new kojic acid-1,3,4-oxadiazole hybrids as tyrosinase inhibitors and their application in the anti-browning of fresh-cut mushrooms. Food Chem.; 2023; 409, 135275. [DOI: https://dx.doi.org/10.1016/j.foodchem.2022.135275]
132. Peng, Z.; Wang, G.; He, Y.; Wang, J.J.; Zhao, Y. Tyrosinase inhibitory mechanism and anti-browning properties of novel kojic acid derivatives bearing aromatic aldehyde moiety. Curr. Res. Nutr. Food Sci.; 2023; 6, 100421. [DOI: https://dx.doi.org/10.1016/j.crfs.2022.100421]
133. Roulier, B.; Pérès, B.; Haudecoeur, R. Advances in the Design of Genuine Human Tyrosinase Inhibitors for Targeting Melanogenesis and Related Pigmentations. J. Med. Chem.; 2020; 63, pp. 13428-13443. [DOI: https://dx.doi.org/10.1021/acs.jmedchem.0c00994] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/32787103]
134. Catalano, M.; Bassi, G.; Rotondi, G.; Khettabi, L.; Dichiara, M.; Murer, P.; Scheuermann, J.; Soler-Lopez, M.; Neri, D. Discovery, affinity maturation and multimerization of small molecule ligands against human tyrosinase and tyrosinase-related protein 1. RSC Med. Chem.; 2021; 12, pp. 363-369. [DOI: https://dx.doi.org/10.1039/D0MD00310G] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/34041485]
135. Chang, Y.; Lee, S.-H.; Na, J.H.; Chang, P.-S.; Han, J. Protection of Grain Products from Sitophilus oryzae (L.) Contamination by Anti-Insect Pest Repellent Sachet Containing Allyl Mercaptan Microcapsule. J. Food Sci.; 2017; 82, pp. 2634-2642. [DOI: https://dx.doi.org/10.1111/1750-3841.13931]
136. Mann, T.; Scherner, C.; Röhm, K.-H.; Kolbe, L. Structure-Activity Relationships of Thiazolyl Resorcinols, Potent and Selective Inhibitors of Human Tyrosinase. Int. J. Mol. Sci.; 2018; 19, 690. [DOI: https://dx.doi.org/10.3390/ijms19030690] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/29495618]
137. Fu, D.; Yuan, Y.; Qin, F.; Xu, Y.; Cui, X.; Li, G.; Yao, S.; Deng, Y.; Tang, Z. Design, synthesis and biological evaluation of tyrosinase-targeting PROTACs. Eur. J. Med. Chem.; 2021; 226, 113850. [DOI: https://dx.doi.org/10.1016/j.ejmech.2021.113850]
138. Burslem, G.M.; Crews, C.M. Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery. Cell; 2020; 181, pp. 102-114. [DOI: https://dx.doi.org/10.1016/j.cell.2019.11.031] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/31955850]
139. Popow, J.; Arnhof, H.; Bader, G.; Berger, H.; Ciulli, A.; Covini, D.; Dank, C.; Gmaschitz, T.; Greb, P.; Karolyi-Özguer, J. et al. Highly Selective PTK2 Proteolysis Targeting Chimeras to Probe Focal Adhesion Kinase Scaffolding Functions. J. Med. Chem.; 2019; 62, pp. 2508-2520. [DOI: https://dx.doi.org/10.1021/acs.jmedchem.8b01826]
140. Farnaby, W.; Koegl, M.; Roy, M.J.; Whitworth, C.; Diers, E.; Trainor, N.; Zollman, D.; Steurer, S.; Karolyi-Oezguer, J.; Riedmueller, C. et al. BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design. Nat. Chem. Biol.; 2019; 15, pp. 672-680. [DOI: https://dx.doi.org/10.1038/s41589-019-0294-6] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/31178587]
141. Luh, L.M.; Scheib, U.; Juenemann, K.; Wortmann, L.; Brands, M.; Cromm, P.M. Prey for the Proteasome: Targeted Protein Degradation—A Medicinal Chemist’s Perspective. Angew. Chem. Int. Ed.; 2020; 59, pp. 15448-15466. [DOI: https://dx.doi.org/10.1002/anie.202004310]
142. Taylor, K.L.; Grant, N.J.; Temperley, N.D.; Patton, E.E. Small molecule screening in zebrafish: An in vivo approach to identifying new chemical tools and drug leads. Cell Commun. Signal.; 2010; 8, 11. [DOI: https://dx.doi.org/10.1186/1478-811X-8-11] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/20540792]
143. Roulier, B.; Rush, I.; Lazinski, L.M.; Pérès, B.; Olleik, H.; Royal, G.; Fishman, A.; Maresca, M.; Haudecoeur, R. Resorcinol-based hemiindigoid derivatives as human tyrosinase inhibitors and melanogenesis suppressors in human melanoma cells. Eur. J. Med. Chem.; 2023; 246, 114972. [DOI: https://dx.doi.org/10.1016/j.ejmech.2022.114972] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/36462443]
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Details
; Dank, Christian 2
; Ielo, Laura 3
1 Dipartimento di Scienze Farmaceutiche, Università degli Studi di Milano, Via Mangiagalli, 25, 20133 Milano, Italy;
2 Institute of Organic Chemistry, University of Vienna, Währinger Strasse 38, 1090 Vienna, Austria;
3 Department of Chemistry, University of Turin, Via P. Giuria 7, 10125 Torino, Italy